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 Obesity is reportedly at epidemic proportions in the U.S. with a myriad of 
potential dietary, lifestyle, and genetic factors contributing to its rise in prevalence.  
In the U.S. 20-25% of adults suffer from obesity and its associated co-morbid 
conditions including cardiovascular disease, diabetes, metabolic syndrome and 
Alzheimer’s disease (AD) making it a leading health care concern. AD affects 
nearly 5.4 million individuals in the U.S. with expected numbers nearly tripling 
over the next few decades and currently represents the sixth leading cause of 
death in the U.S. and fifth amongst individuals 65+. A form of autosomal 
dominant AD is associated with mutations in the gene coding for the ubiquitously 
expressed transmembrane protein, amyloid precursor protein (APP).  Proteolytic 
processing of APP provides the beta amyloid (Aβ) peptide that is characteristic of 
AD plaque pathology. Amyloid precursor protein (APP) derived Aβ peptides have 
been extensively investigated in Alzheimer’s disease pathology of the brain. 
However, the function of full length APP in the central nervous system remains 
unclear. Even less is known about the behavior of this ubiquitously expressed 
protein and it metabolites outside of the central nervous system. Therefore, we 
sought to broaden our understanding of the expression and function of APP and 
its proteolytic fragments in specific non-neuronal tissues. Although the majority of 
research effort is currently focused on neuronal Aβ production and its effects on 
xx 
 
cells, prior work in our lab demonstrated a novel role for APP in regulating the 
phenotype of monocytic lineage cells. Therefore, we hypothesized that APP can 
behave as a proinflammatory receptor on these cells involved in modulating their 
tissue infiltration and differentiation. Based upon the fact that midlife obesity is a 
risk factor for Alzheimer’s disease and both obese adipose tissue and 
Alzheimer’s disease brains share a common presence of increased, reactive 
macrophage and microglia, respectively, we hypothesized that APP may have a 
common role in both diseases regulating the infiltration or proinflammatory 
activation of microglia and macrophage characterizing both diseases. Indeed, 
recent data has demonstrated that APP levels are increased in adipose tissue 
from obese versus control individuals. To test this idea we utilized a high fat diet 
feeding paradigm on both C57BL6 wild type and APP-/- mice to examine any role 
for APP and high fat diet dependent changes in adipose tissue, brain, and 
intestine. In vivo changes were compared to those obtained using primary cells 
isolated from the murine models.  Collectively, these data suggest that APP does 
regulate microglia and macrophage phenotype in a manner responsible for 
altering their behavior in tissue specific fashion. This suggests that immune-
related functions of APP may be a common type of pathophysiology linking the 






APP Expression, Processing, and Structure 
Amyloid precursor protein (APP) is a type I integral membrane protein with 
a large extracellular N-terminal domain, a hydrophobic transmembrane domain, 
and a short C-terminus intracellular domain (Kang et al., 1987a, Dyrks et al., 
1988) (Figure 1). There are three major isoforms of the protein derived from 
alternative splicing, APP751, APP770, APP695, with APP695 demonstrating 
highest levels of expression in brain (Ponte et al., 1988, Tanaka et al., 1988, 
Tanaka et al., 1989).  As previously reviewed (Zheng and Koo, 2011, Zhang et 
al., 2012), APP undergoes post-translational processing via two pathways, the 
non-amyloidogenic and the amyloidogenic. In the non-amyloidogenic pathway, 
APP is sequentially cleaved first by α-secretase (ADAMs) to generate an N-
terminal sAPP-α fragment. The remaining C83 C-terminal fragment is further 
cleaved by γ-secretase (Presenilin1 or Presenilin2, Presenilin enhancer 2 
(PEN2), Anterior pharynx-defective 1 (APH1) and Nicastrin) to release a P3 
peptide and its C-terminal intracellular counterpart, the APP intracellular domain 
(AICD). In the amyloidogenic processing pathway, APP is again sequentially 
cleaved but first by the β-secretase (BACE1) to yield the N-terminal sAPP-β 
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fragment. The remaining C99 C-terminal fragment undergoes є and γ cleavages 
by γ-secretase to release the amyloid beta (Aβ) 1-40/42 peptides and an AICD. A 
characteristic accumulation of Aβ peptides in the brains of AD patients has 
helped to draw research focus to these particular peptide metabolites of APP. 
Finally, APP can also be processed by caspase 3 to release cytotoxic C31 and 
Jcasp fragments. Amyloid precursor protein and mRNA have been shown to be 
expressed in the brain, thymus, heart, muscle, lung, kidney, adipose tissue, liver, 
spleen, skin, and intestine (Selkoe et al., 1988, Joachim et al., 1989, Yamada et 
al., 1989, Sandbrink et al., 1994, Akaaboune et al., 2000, Herzog et al., 2004, 
Galloway et al., 2007, Lee et al., 2008b). Therefore, even though the function 
and processing of APP in neurons may appear particularly relevant to the study 
of AD, the wide-spread expression of the protein suggests it has a broader role in 
both normal and disease physiology. 
 
APP Function in the CNS 
Much of the study of amyloid precursor protein (APP) has focused on 
changes in the central nervous system during Alzheimer’s disease (AD) 
pathology. APP is expressed in the brain primarily by neurons (LeBlanc et al., 
1991) where it can be metabolized to Aβ1-40 and 1-42 peptides which aggregate 
to form amyloid plaques characteristic of AD (Kang et al., 1987b). Moreover, 
mutations in the gene coding for APP (Goate et al., 1991) or its protease 
presenilins (Schellenberg et al., 1992, Levy-Lahad et al., 1995, Sherrington et al., 
1995) are responsible for a rare autosomal dominant form of disease.  
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As previously reviewed (Zheng and Koo, 2011, Zhang et al., 2012), in the 
central nervous system (CNS) full length APP has been suggested to function as 
a cell surface receptor contributing to cell adhesion and cell-cell interactions via 
its extracellular domain possibly through trans-dimerization. The C-terminus of 
APP contains a YENPTY sequence between residues 682 and 687 that is a 
consensus sequence for a phosphotyrosine binding domain interaction. The N-
terminal fragment, sAPP-α, is neuro-protective, promotes neurite outgrowth and 
synaptogenesis, facilitates learning and memory, acts as a growth factor and 
regulates cell adhesion (Mattson et al., 1993, Furukawa et al., 1996a, Furukawa 
et al., 1996b, Mattson, 1997, Herzog et al., 2004, Siemes et al., 2006, Gakhar-
Koppole et al., 2008, Ma et al., 2009). On the other hand, the N-terminal sAPP-β 
fragment can stimulate axonal pruning and neuronal cell death (Nikolaev et al., 
2009). APP cleavage to generate the Aβ peptide can lead to peptide-mediated 
neurotoxicity, neurofibrillary tangle formation and synaptic loss (Selkoe et al., 
1988, Shankar and Walsh, 2009). The APP intracellular domain (AICD) fragment 
that is often generated during proteolytic processing is capable of behaving as a 
transcription factor, controlling cell death and neprilysin-mediated Aβ 
degradation, altering calcium and ATP homeostasis, and regulating intracellular 
trafficking and cytoskeletal dynamics (Gandy et al., 1988, Suzuki et al., 1994, 
Iijima et al., 2000, Lu et al., 2000, Inomata et al., 2003, Pardossi-Piquard et al., 
2005, Xu et al., 2007). However, considerably less work has been published 
describing the function and expression of full-length APP or its cleavage products 
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outside the central nervous system in spite of the well-recognized ubiquitous 
expression pattern. 
 
APP Function and Aβ Pathology in Skin 
 APP expression in the mammalian epidermis is predominantly in basal 
keratinocytes, but can also be found in the melanotyes and in melanoma cells 
(Hoffmann et al., 2000, Herzog et al., 2004).  APP is also expressed in vitro in 
the immortalized human keratinocyte cell line, HaCaT, as well as in proliferating 
primary keratinocytes (Herzog et al., 2004).  Aβ deposits have been reported 
beneath the epidermal/dermal junction as well as near small blood vessels and 
glandular structures in human tissue (Joachim et al., 1989).  
APP function has been previously reviewed (Herzog et al., 2004), in the 
epidermis where it appears that APP promotes cell adhesion to several 
components of the extracellular matrix based upon its in vitro interactions with 
perlecan, laminin, collagen type IV, and entactin (Narindrasorasak et al., 1991, 
Narindrasorasak et al., 1992, Narindrasorasak et al., 1995, Beher et al., 1996). 
Studies using wild type and APP-/- mice demonstrate that APP may also function 
as a membrane receptor and regulate behavior of the axonal transport protein, 
kinesin-I, which mediates movement of membrane-bound compartments such as 
melanosomes along microtubules (Kamal et al., 2001). Interestingly, APP also 
appears to regulate copper homeostasis as suggested by its in vitro ability to 
reduce Cu(II) to Cu(I) leading to oxidative stress and apoptosis in the basal 
epidermis in human keratinocytes (Multhaup et al., 1996, Kagan et al., 2002).  
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In addition to these functions attributed to full length protein, the APP 
fragment, sAPPα, promotes human keratinocyte proliferation and migration and 
regulates melanocyte function in vitro (Lauffenburger and Horwitz, 1996, 
Hoffmann et al., 2000, Quast et al., 2003, Siemes et al., 2006). This is consistent 
with the fact that APP-/- keratinocytes have reduced proliferative and cell 
substrate adhesion potential. These findings suggest that sAPPα belongs to a 
family of structurally similar cysteine-rich growth factors for epidermal 
keratinocytes involved in growth, differentiation and wound repair (Rossjohn et 
al., 1999).   
APP or its metabolites may also play some role in epidermal pathology. 
For instance, APP levels are upregulated in keratinocytes in psoriasis, a very 
common chronic inflammatory human skin disease in which keratinocyte 
proliferation and differentiation are perturbed leading to alteration in epidermal 
thickness and composition (Romanowska et al., 2009). Processing of APP to Aβ 
in vitro in human psoriasis patient keratinocytes increases transcription of 
kynureninase, which can induce an inflammatory skin reaction (Romanowska et 
al., 2009). Increased APP expression also correlates with advanced melanoma 
progression in human tissues and downregulation by RNA interference in vitro in 
human melanoma cell lines results in terminal and irreversible differentiation 
(Botelho et al., 2010).  
APP processing and Aβ release has also been shown to be regulated by 
PKC activity in cultured skin fibroblasts from familial Alzheimer’s disease (FAD) 
patients, in which phorbol ester stimulation of PKC-α activity increases sAPP-α 
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and decreases Aβ secretion (Gasparini et al., 1998). Aβ secretion is basally 
elevated in cultured skin fibroblasts from FAD patients, suggesting that FAD has 
a deficit in PKC activity. FAD cultured fibroblasts also have increased total 
membrane bound calcium with attenuated calcium uptake as well as increased 
lactate production and altered glucose utilization compared to non-AD controls. 
This suggests that APP may be involved in regulating a disease phenotype in 
FAD epidermis (Gasparini et al., 1998). 
Collectively, these findings from the skin indicate that APP and its 
metabolites have a role in regulating epidermal cell phenotypes with a significant 
ability to modulate proliferative and migratory behavior. Disease-associated 
changes in expression or processing of APP correlate with perturbations of these 
behaviors in a variety of diseases. 
 
APP Function and Aβ Pathology in Muscle 
APP is also present in the pre and post synaptic compartments of mouse 
skeletal muscle and in cultured murine myogenic cells (Akaaboune et al., 2000).  
APP is detected as early as murine embryonic day 16 (E16) in the cytoplasm of 
developing muscle fibers. By E18 APP distributes throughout the muscle fiber 
sarcoplam and at birth (P0) APP immunoreactivity begins localizing to the 
neuromuscular junctions (NMJs). By postnatal day 5 (P5), APP immunoreactivity 
restricts to NMJs where it colocalizes with acetylcholine receptors (AChRs).  In 
this NMJ localization, APP expression continually increases into adulthood 
(Akaaboune et al., 2000). Not surprisingly, APP expression is required for NMJ 
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synapse formation of murine motor neurons (Wang et al., 2005b). In the absence 
of APP, murine NMJs demonstrate aberrant localization of presynaptic proteins 
with postsynaptic AChR clusters and decreased synaptic vesicles at presynaptic 
terminals and a significant increase in synaptic dysfunction (Wang et al., 2005b).   
These critical roles of APP in NMJ function suggest that altered 
expression or behavior of APP or its metabolites may be involved in disease. 
Muscle fibers of patients with the debilitating skeletal muscle disorder, inclusion-
body myositis (IBM), have intrafiber “plaque-like” accumulation of intracellular Aβ 
which is preferentially greater for Aβ42 than Aβ40 (Askanas and Engel, 2006). 
Accordingly, APP and Aβ are suggested to accumulate in skeletal muscle of IBM 
patients where they are hypothesized to act through a variety of mechanisms to 
promote myofiber degeneration, atrophy, and death (Greenberg, 2010). In 
addition, Aβ40 and Aβ42 levels are elevated in the temporalis muscles of AD vs. 
nondemented individuals  suggesting some perturbation of neuromuscular 
function (Kuo et al., 2000).  
These data from muscle indicate that APP and its metabolites have not 
only a developmental role in NMJ formation but also may be critically involved in 
regulating normal transmission at this specialized form of synapse. Moreover, 
altered expression or accumulation of APP or its breakdown products in muscle, 






APP Function and Aβ Pathology in Adipose Tissue 
 APP and its Aβ fragments are also expressed in human adipose tissue 
adipocytes and macrophages (Lee et al., 2008b). Obesity upregulates APP 
levels in vivo in human adipose tissue, which correlates with insulin resistance, 
hyperinsulinemia, and an increase in the expression profile of the 
proinflammatory genes, MCP-1, MIP-1α, and IL-6, in human adipocytes in vitro 
(Lee et al., 2008b). Elevated human adipocyte APP gene expression in vivo also 
correlates with increased plasma Aβ40 levels (Lee et al., 2009b). TNFα 
stimulation increases APP protein levels in vitro in 3T3-L1 adipocytes in a dose-
dependent manner (Sommer et al., 2009). These data from human studies 
indicate that APP expression in adipose tissue appears to be up-regulated during 
pro-inflammatory conditions, such as obesity, and is positively regulated by direct 
proinflammatory stimulation of adipocytes. However, the function of APP or its 
metabolites basally or during proinflammatory upregulation in adipose tissue 
remains unclear. 
 
APP Function and Aβ Pathology in Intestine 
APP and Aβ levels are increased in absorptive columnar epithelial cells in 
mice fed a high fat diet that is enriched in saturated fat and cholesterol. However, 
Aβ levels are attenuated by fasting for 65hr suggesting that APP or its 
metabolites may regulate chylomicron biosynthesis (Galloway et al., 2007). Aβ 
immunoreactivity colocalizes with apo B in small intestine enterocytes along the 
lengths of the villi and Aβ levels are attenuated in mice fed a diet free of 
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saturated fat but supplemented with cholesterol, again supporting the idea that 
Aβ is involved in chylomicron biosynthesis (Galloway et al., 2009, Pallebage-
Gamarallage et al., 2009). Enterocyte Aβ immunostaining localizes to perinuclear 
regions suggesting a location within the golgi apparatus or rough endoplasmic 
reticulum (Galloway et al., 2007).  There may also be some contribution of APP 
or its metabolites to traditionally non-intestine related disease. For instance, Aβ 
immunoreactive plaques are detectable in the intestines of AD patients (Joachim 
et al., 1989). These findings indicate that APP expression and metabolite 
generation are not limited to a particular cell type in the digestive system with a 
myriad set of functions attributed to these proteins ranging from specific 
absorption and gut motility to immune response. 
The mammalian intestines are not only characterized by a unique enteric 
nervous system (Harrington et al., 2010, Tomita et al., 2010) and APP isoform 
expression (Yamada et al., 1989, Arai et al., 1991) but also an abundance of 
resident immune cell types, including macrophages necessary for monitoring 
resident and foreign microbial exposure (Santaolalla et al., 2010). Although Aβ in 
the intestine and brain have been reported (Gravina et al., 1995, Johnson-Wood 
et al., 1997, Li et al., 2004, Galloway et al., 2007, Galloway et al., 2009, 
Hellstrom-Lindahl et al., 2009), the role of APP in the enteric nervous system is 
not clear. Our laboratory has demonstrated that APP on monocytes is critical for 
adhesion dependent activation, extravasation through the endothelium and 
acquisition of a reactive phenotype (Sondag and Combs, 2004a, 2006b, 2010a). 
Therefore, APP expression in immune cells in the brain and intestinal tissue likely 
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regulates the proinflammatory environment in these tissues. Indeed, it was not 
unreasonable to predict that the proinflammatory environment and 
microglia/macrophage numbers are to some degree dependent upon APP 
expression or metabolism.  
 
APP Function and Macrophage/Microglia 
Our prior studies (Sondag and Combs, 2004b, 2006a, 2010b) as well as 
others (Bauer et al., 1991, Bullido et al., 1996, Vehmas et al., 2004, Spitzer et al., 
2010) have demonstrated that APP is also expressed on immune cells where it 
appears to play a role in regulating cellular phenotype. For example, expression 
on monocytic lineage cells appears to regulate the ability of these cells to interact 
with extracellular matrix and mediate various cell-cell interactions (Austin and 
Combs, 2010, Sondag and Combs, 2010b). In addition, APP expression 
increases in both macrophages and microglia in the presence of a reactive, 
stimulatory environment (Haass et al., 1991, Banati et al., 1994a, Monning et al., 
1994, Banati et al., 1995a, Banati et al., 1995b, Gehrmann et al., 1995a, 
Gehrmann et al., 1995b, Monning et al., 1995, Itoh et al., 2009).  
We have also observed that agonist antibody stimulation of APP leads to 
a diverse change in proinflammatory protein expression and cytokine secretion 
as well as release of Aβ peptides from monocytic cells (Sondag and Combs, 
2004b, 2006a). Recently, others have suggested that secreted Aβ peptides are 
anti-microbial (Soscia et al., 2010) fitting well with the ability of immune cells to 
make the peptides upon activating ligand stimulations (Sondag and Combs, 
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2006a, Spitzer et al., 2010). Finally, a variety of studies have demonstrated that 
APP metabolites and Aβ peptides in both their fibrillar and oligomeric forms are 
potent activating stimuli for macrophages, monocytes, and microglia (Klegeris et 
al., 1994, Yan et al., 1998, Combs et al., 1999, Yates et al., 2000, Smits et al., 
2001, Yazawa et al., 2001, Ikezu et al., 2003, Uryu et al., 2003, Xiong et al., 
2004, Floden and Combs, 2006, Sondag et al., 2009, Maezawa et al., 2010). 
Collectively, these data suggest that APP and its proteolytic products may serve 
as regulators of proinflammatory phenotype in particular immune cells. 
 
Amyloid Precursor Protein and Alzheimer’s Disease 
Alzheimer’s disease is clinically described as loss of memory, progressive 
impairment of cognition and various behavioral and neuropsychiatric 
disturbances (Saijo and Glass, 2011).  A hallmark of Alzheimer’s disease (AD) 
brains is the accumulation of amyloid beta (Aβ) plaques and neurofibrillary 
tangles composed of hyperphosphorylated tau (Perry et al., 1989, Joachim et al., 
1991, Paloneva et al., 2002, de Haas et al., 2008). Aβ is a peptide cleavage 
product of amyloid precursor protein (APP) which aggregates to form 
extracellular plaques within the AD brain (Kang et al., 1987b). Aβ serves as a 
potent proinflammatory stimulus for microglia lending support to the idea that the 
reactive microgliosis in AD brains is due to Aβ stimulation (Meda et al., 1995, 
Bitting et al., 1996, Lorton et al., 1996, Combs et al., 1999, Lorton et al., 2000, 




Obesity and Alzheimer’s Disease 
Alzheimer’s disease (AD) affects nearly 5.3 million individuals in the U.S. 
with expected numbers nearly tripling over the next few decades and currently 
represents the seventh leading cause of death in the U.S. (Alzheimer Association 
Annual Report, 2010). Unfortunately, the severity of this disease pales in 
comparison to the number of adults in the U.S. suffering from obesity (20-25% of 
adults, CDC 2008 report) and its associated co-morbid conditions including 
cardiovascular disease (est. 81 million, American Heart Association 2010 update) 
and diabetes (est. 23.6 million, CDC, 2007 update). Deaths associated with 
obesity related cardiovascular disease and stroke are the number one cause of 
death in the U.S. Although they may appear initially as disparate conditions, the 
risk of developing Alzheimer’s disease is increased by middle age obesity, type II 
diabetes, and cardiovascular/cerebrovascular disease (Despres, 2003, Craft, 
2005, Kivipelto et al., 2005, Despres and Lemieux, 2006, Razay et al., 2006, 
Wolozin and Bednar, 2006, Gunstad et al., 2007, Luchsinger and Mayeux, 2007, 
Razay et al., 2007, Whitmer, 2007, Whitmer et al., 2007, Beydoun et al., 2008, 
Despres et al., 2008, Luchsinger, 2008, Profenno and Faraone, 2008, Despres, 
2009, Fitzpatrick et al., 2009, Luchsinger and Gustafson, 2009b, a, Mattson, 
2009, Ross and Despres, 2009, Sommer et al., 2009). This data offers the 
provocative idea that a common mechanism of pathophysiology is shared 
between all these conditions.  
Obesity, particularly in mid-life, is an increased risk factor for AD 
independent of other conditions (Kivipelto et al., 2005, Whitmer, 2007, Whitmer 
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et al., 2007, Beydoun et al., 2008, Profenno and Faraone, 2008, Fitzpatrick et al., 
2009, Profenno et al., 2010). Particular saturated versus unsaturated fat 
ingestion at midlife also increases the risk of developing AD (Laitinen et al., 2006, 
Eskelinen et al., 2008). In addition, metabolic syndrome and diabetes, often 
comorbid with obesity, are factors of increased risk for AD in some (Razay et al., 
2006, 2007, Profenno and Faraone, 2008, Profenno et al., 2010) but not all 
studies (Raffaitin et al., 2009). Interestingly, late life obesity and metabolic 
syndrome are either not risk factors or actually decrease the risk of AD in several 
studies (Fitzpatrick et al., 2009, Hughes et al., 2009, Forti et al., 2010). Others 
have reported that obesity itself is associated with poorer cognitive performance 
in humans (Jeong et al., 2005, Gunstad et al., 2006, Gunstad et al., 2007) as well 
as decreased brain volumes (Gunstad et al., 2008) independent of age or 
disease. In spite of this abundance of correlational data, a particular mechanism 
linking the pathophysiology of obesity to the brain changes of AD remains 
unclear. 
 
Amyloid Precursor Protein and Obesity 
Obesity is reportedly at epidemic proportions in the U.S. with a myriad of 
potential dietary and lifestyle factors contributing to its rise in prevalence (Hill and 
Peters, 1998, Caterson and Gill, 2002, Brantley et al., 2005, Selassie and Sinha, 
2011). However, genetic factors do also have a significant impact on this disorder 
(Farooqi and O'Rahilly, 2006, Frayling et al., 2007, Loos et al., 2008, Stoger, 
2008, Lee, 2009, Lindgren et al., 2009, Choquet and Meyre, 2010, Beyerlein et 
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al., 2011, Farooqi, 2011, Herrera et al., 2011, Ramachandrappa and Farooqi, 
2011). The fact that it is a risk factor for diabetes, heart disease, metabolic 
syndrome and Alzheimer's disease make it a leading health care concern 
(Despres, 2003, Craft, 2005, Kivipelto et al., 2005, Despres and Lemieux, 2006, 
Razay et al., 2006, Wolozin and Bednar, 2006, Gunstad et al., 2007, Luchsinger 
and Mayeux, 2007, Razay et al., 2007, Whitmer, 2007, Whitmer et al., 2007, 
Beydoun et al., 2008, Despres et al., 2008, Luchsinger, 2008, Profenno and 
Faraone, 2008, Despres, 2009, Fitzpatrick et al., 2009, Luchsinger and 
Gustafson, 2009a, b, Mattson, 2009, Ross and Despres, 2009, Sommer et al., 
2009).  
Recent data suggests that APP expression or function may also be 
involved in the pathophysiology of obesity. Obesity is characterized by 
inflammation, adipocyte hypertrophy and infiltration of immune cells, particularly 
macrophage.  It is known that adipose tissue (Lee et al., 2008a, Lee et al., 
2009a, Sommer et al., 2009) and adipocyte cell lines (Sommer et al., 2009) 
express APP. More importantly, adipose APP and Aβ1-40 plasma levels increase 
in obese individuals (Lee et al., 2008a, Lee et al., 2009a) and plasma Aβ1-42 
and 1-40 levels correlate with increased body fat in humans (Balakrishnan et al., 
2005, Leahey et al., 2007). Rodent studies have examined the brain in a variety 
of diet-induced obesity paradigms confirming that brain changes leading to 
increased Aβ levels occur in both AD transgenic (Levin-Allerhand et al., 2002, 
Kohjima et al., 2010) and wild type mice (Thirumangalakudi et al., 2008). These 
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findings indicate that changes in APP expression or function may be coordinated 
across diverse tissue types. 
 
Adipose Tissue 
 Adipose tissue is considered an endocrine organ capable of secreting 
hormones and cytokines to mediate metabolic, hemodynamic, and hemostatic 
disturbances as well as inflammatory and immune responses. The primary cells 
of adipose tissue are adipocytes which are thought to arise from mesenchymal 
stem cells (MSCs) by a sequential differentiation pathway in which appropriate 
developmental triggers cause the MSCs to commit to the adipocyte lineage and 
become adipoblasts or preadipocytes (Cinti, 2012). These adipoblasts or 
preadipoblasts then transition through four phases: growth arrest, clonal 
expansion, early differentiation, and terminal differentiation (Cinti, 2012). The 
conversion from adipoblasts to adipocytes is stimulated by both PPARγ and 
C/EBP to become either white or brown adipocytes, however the exact molecular 
events that govern white versus brown differentiation has yet to be elucidated 
(Gesta et al., 2007).  Brown adipose tissue (BAT) is highly vascularized, 
innervated and consists of polygonal cells with a roundish nucleus and several 
cytoplasmic lipid droplets characterized by large mitochondria packed with 
cristae (Cinti, 2012). BAT is unique in its expression of uncoupling protein 1 
(UCP1) which can uncouple oxidative phosphorylation from ATP synthesis and 
thereby resulting in the production of heat (thermogenesis) (Cannon and 
Nedergaard, 2004, Ricquier, 2005, Frontini et al., 2007). White adipose tissue 
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(WAT), on the otherhand, is five to six times less vascularized, is characterized 
by leptin and S100-β immunoreactive spherical cells with ~90% of their volume 
comprising of a single cytoplasmic lipid droplet and a ‘squeezed’ nucleus in order 
to store energy for the metabolic needs of the organ (Cinti, 2012). 
 To store energy, lipoprotein lipase (LPL) molecules on the endothelial 
surface of the capillary bind to a chylomicron and hydrolyze the triacylglycerol 
(Triglyceride) portion of the particle (Smith et al., 2006). This causes fatty acids 
(FAs) to be released into either the adipocyte where they are esterified into 
triacylglycerol or they bind to albumin within the capillary space to become part of 
the albumin-FA complex which can also enter the adipocyte or move into 
systemic circulation (Smith et al., 2006). Triacylglycerol within the adipocyte can 
then be hydrolyzed to FAs by hormone-sensitive lipase (HSL) or triacylglycerol 
lipase (Smith et al., 2006). When food intake exceeds energy expenditure, the 
adipose stores more triacylglycerol. Conversely when expenditure exceeds food 
intake, adipose releases more triacylglycerol. To meet this expansion of energy, 
the existing adipocytes increase in size. In addition, there is increased formation 
of new white adipocytes from pre-adipocytes or from a direct transformation of 
brown adipocytes to white adipocytes that occurs (Cinti et al., 1997, Hausman et 
al., 2001, Bachman et al., 2002).  The excessive storage of triacylglycerol leads 
to obesity and associated conditions (Cinti, 2012). 
Typically macrophage comprise 10-15% of the immune cells in lean 
adipose tissue, however in obese adipose tissue 45-60% of the cells are 
macrophage (Lumeng et al., 2007, Chawla et al., 2011).  Macrophage can have 
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two distinct phenotypes M1 and M2. M1 is the classically activated, 
proinflammatory phenotype induced by LPS and IFNγ, typically found in “crown-
like” structures around dying adipocytes in which they have enhanced cytokine 
production of TNFα, IL-6, IL-12 and generate reactive oxygen species to activate 
iNOS (Mantovani et al., 2004, Gordon and Taylor, 2005). M2 is the alternatively 
activated less inflammatory phenotype induced by IL-4 or IL-13. M2 macrophage 
are typically uniformly dispersed throughout the adipose tissue and have 
enhanced cytokine production of IL-10, IL-1β and blocks iNOS activity (Gordon, 
2003). Upon high fat feeding adipose tissue macrophage undergo a phenotypic 
switch from an anti-inflammatory M2 polarization to a proinflammatory M1 
polarization state thereby losing their protective capacity (Lumeng et al., 2007). 
These findings, in conjunction with the previously described expression of APP 
on macrophage and adipocytes, suggest that APP may play a role in this 
phenotypic switching of macrophage polarization or fatty acid uptake in this 
tissue. 
 
Brain-Gut-Adipose-Tissue Communication Pathways 
The brain is responsible for controlling the metabolic inputs to maintain the 
peripheral energy state. To maintain energy expenditure, the brain generates 
neuronal and hormonal signals in response to the short-term signals produced by 
the gut and the long-term signals produced by the adipose tissue (Yi and Tschop, 
2012).  In the hypothalamus located within the forebrain reside a number of 
nuclei, particularly the arcuate nucleus and the ventromedial hypothalamus, 
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which express adipokine receptors that can bind to adipokines such as leptin that 
are released from adipose tissue directing the brain to suppress appetite and 
stimulate energy expenditure (Gautron and Elmquist, 2011). In the nucleus 
tractus solitariuses located within the hindbrain resides the dorsal motor nucleus 
of the vagus complex which receives signals from the gastrointestinal system via 
vagal afferents or the circulation delivering satiety hormones directing the brain to 
initiate or terminate feeding (Berthoud et al., 2006). Therefore communication 
between these organs is vital to controlling metabolic disorders. 
 
Enteric Nervous System 
Although APP processing has been described in the central nervous 
system, the process and consequences of APP and Aβ accumulation in the 
enteric nervous system have not been extensively studied. Elderly are often 
afflicted with debilitating intestinal disorders such as constipation, fecal 
incontinence, and evacuation (Camilleri et al., 2008, Roach and Christie, 2008, 
Everhart and Ruhl, 2009b, a) which could be due to a degenerating enteric 
nervous system. The enteric nervous system is homologous to the central 
nervous system sharing similar embryology, morphology and neurochemistry 
(von Boyen et al., 2002). It heavily innervates the small intestine and controls 
virtually all gastrointestinal (GI) functions, including motility, secretion, blood flow, 
mucosal growth and local immune system cell behavior (Goyal and Hirano, 
1996). Indeed, the small intestine is host to multiple cells of the immune system 
which, through interactions with the enteric neurons, can also evoke alterations in 
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gut function (Goyal and Hirano, 1996). Therefore, these characteristics along 
with the knowledge that elderly, including AD patients (Johanson et al., 1992, 
Sonnenberg et al., 1994), experience GI dysfunction suggest that APP and Aβ 
may also accumulate in the enteric nervous system leading to immune cell 
activation and neuronal dysfunction in the digestive tract not unlike that observed 
in the diseased brain. 
 
Macrophage and Microglia 
 Macrophage cells are of monocytic origin arising from bone marrow, from 
which they migrate into circulation, follow the general paradigm of leukocyte 
adhesion and trafficking, which involves rolling, adhesion and transmigration via 
integrins and other adhesion molecules into various tissues throughout the body 
(Ley et al., 2007).  Based on their anatomical location and functional phenotype 
macrophages can be divided into subpopulations. For example, osteoclasts in 
bone, alveolar macrophages in the lungs, histiocytes in interstitial connective 
tissue, Kupffer cells in the liver, microglia in the brain, intestinal macrophage in 
the intestine, splenic macrophage in the spleen, adipocyte macrophage in 
adipose tissue, etc, are all forms of tissue specialized macrophage (Peranzoni et 
al., 2010, Murray and Wynn, 2011). Macrophages primary functions are to 
provide immune surveillance by: (1) ingesting and processing foreign materials, 
dead cells and debris; (2) recruiting additional macrophages in response to 
inflammatory signals; (3) antigen presenting; and (4) immune suppression 
(Murray and Wynn, 2011). Macrophages also work together to maintain tolerance 
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to the gut flora and food, by being bathed in IL-10 to mute any inflammatory 
response (Murray and Wynn, 2011). 
Microglial cells are also of monocytic origin arising from bone marrow, 
from which they migrate and invade into the brain during early embryogenesis or 
via vessels or white matter tracts into the mature brain during homeostasis and 
inflammation (Kettenmann et al., 2011, Shi and Pamer, 2011). Once inside the 
brain they are transformed into the branched, ramified morphological phenotype 
or “resting microglia” until they are activated by a pathological event in which they 
undergo another transformation into an amoeboid morphology (Kettenmann et 
al., 2011).  The “resting microglia” has a small soma with fine cellular processes 
which are used to scan the environment without disturbing the fragile neuronal 
circuitry. However, the “activated microglia” have reduced cellular processes in 
their amoeboid appearance in order to become more motile and actively move 
throughout the brain toward sites of pathological events (Kettenmann et al., 
2011).  In rodents, 5-20% of the total glial cells in the brain are microglia (Lawson 
et al., 1990, Perry and Gordon, 1991). Microglial cells are capable of migration, 
proliferation, and phagocytosis.  Microglia can also: (1) induce and rearrange 
their surface molecules in order to communicate via cell-cell and cell-matrix 
interactions; (2) change expression of their intracellular enzymes; (3) release 
multiple factors or compounds that are proinflammatory, immunoregulatory, 
chemoattractive, or neurotrophic; (4) remove synapses from axotomixed 
motoneurons, i.e. “synaptic stripping”, in order to remodel neuronal connectivity; 
and (5) participate in both innate and adaptive immune responses (Kettenmann 
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et al., 2011). The fact that these cells express APP, suggests that APP and its 
proteolytic products may serve as regulators in the multitude of functions or the 
proinflammatory phenotype of these particular immune cells.  
 
Hypothesis 
We predict that APP and its proteolytic fragments play a central role in the 
inflammatory pathophysiology of not only AD but also obesity. Although the 
proteolytic fragments are highly studied, the functions of the full length 
ubiquitously expressed APP protein have yet to be elucidated. The brain 
expresses high levels of neuronal APP, and recent data has demonstrated that 
APP levels are increased in adipose tissue from obese versus control individuals. 
As already mentioned, prior work in our lab has demonstrated a novel role for 
APP in regulating the phenotype of monocytic lineage cells. Therefore, we 
hypothesized that APP can behave as a proinflammatory receptor on these cells 
involved in modulating their tissue infiltration and differentiation. Based upon the 
fact that midlife obesity is a risk factor for Alzheimer’s disease and both obese 
adipose tissue and Alzheimer’s disease brains share a common presence of 
increased, reactive macrophage and microglia, respectively, we hypothesized 
that APP may have a common role in both diseases regulating the infiltration or 












Anti-β-Amyloid Precursor Protein (APP) and anti-occludin antibodies were 
purchased from Invitrogen (Carlsbad, CA, USA). Anti-mouse IgM (goat), anti-
rabbit (goat), anti-goat (bovine), anti-rat (goat), and anti-mouse (bovine) 
horseradish peroxidase-conjugated secondary antibodies, Cox-2, CD40, CD14, 
TLR4, CD36, GAPDH, cSrc, PPARγ, glut-4, arginase-1, Caveolin, VLDLR, 
CFABP,  α-tubulin, and β actin antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  Elite Vectastain ABC Avidin and Biotin, 
Vector VIP, Vector DAB, biotinylated anti-rabbit, anti-mouse, and anti-rat 
antibodies were purchased from Vector Laboratories Inc (Burlingame, CA, USA).  
Synaptophysin and βIII tubulin antibodies were purchased from Chemicon 
international, Inc (Temecula, CA, USA).  CD45 antibody was purchased from BD 
Biosciences Pharmingen (San Jose, CA, USA).  TNF-α, DLK, FABP4, APOE, 
FAS, adiponectin, leptin, Y188, and LPL antibodies were purchased from Abcam 
Inc (Cambridge, MA, USA).  CD68 antibody was purchased from AbD Serotec 
(Oxford, UK).  iNOS antibody was purchased from Alexis Biochemicals (San 
Diego, CA, USA).  GFAP, BACE, pAKT, AKT, and PSD95 antibody was 
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purchased from Cell Signaling Technology Inc (Danvers, MA, USA).  MAP2 
antibody and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). CD3, CD11c and 
FATP4 antibodies were purchased from Abcam Inc (Cambridge, MA, USA).  
TLR2 antibody was purchased from Imgenex (San Diego, CA, USA).  pTyr 
antibody was purchased from Millipore (Billerica, MA, USA). PHF-1 antibody was 
a gift from Dr. Peter Davies (Albert Einstein College of Medicine, NY).  Cox-2 and 
Prostaglandin (PG) E2d4 were purchased from Cayman Chemical (Ann Arbor, 
MI, USA). β-Amyloid (Aβ), rodent specific polyclonal antibody (SIG-39151) was 
purchased from Covance (Emeryville, CA, USA). Oligomer antibody (A11) was 
purchased from Invitrogen (Camarillo, CA, USA). Aβ clone 4G8 was purchased 
from Covance (Emeryville, CA, USA). Phospotyrosine (4G10) antibody was 
purchased from Upstate (Temecula, CA, USA). IBA-1 antibody was purchased 
from Wako Chemicals (Richmond, VA, USA). Fibril antibody (OC) antibody was 
generously provided by Dr. Rakez Kayed (U. Texas, Galveston, USA) (Kayed et 
al., 2007). LRP (H4 clone) antibody was generously provided by Dr. Isa Hussaini 
(U. Virginia, Charlottesville, USA). 
 
Mice 
APPtm1Dbo/J homozygous (APP-/-) mice, APP/PS1 (APPswe,PSEN1dE9) 
mice, and wild type (C57BL6) mice were purchased from Jackson Laboratory.  
The APP/PS1 (APPswe,PSEN1dE9) transgenic animals express the human 
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Tissue samples were lysed using ice cold RIPA buffer (20mM Tris, pH 7.4, 
150mM NaCl, 1mM Na3VO4, 10mM NaF, 1mM EDTA, 1mM EGTA, 0.2mM 
phenylmethylsulfonyl fluoride, 1% Triton, 0.1% SDS, and 0.5% deoxycholate) 
with protease inhibitors (AEBSF 1mM, Aprotinin 0.8μM, Leupeptin 21μM, 
Bestatin 36μM, Pepstatin A 15μM, E-64 14μM). For intestine tissue samples 
50U/mL DNAse1 (Amresco Inc, Solon, OH, USA) was also added to the RIPA 
buffer with protease inhibitors.  To remove insoluble material cell lysates were 
sonicated and centrifuged (14,000 rpm, 4˚C, 10 min). The Bradford method 
(Bradford, 1976a) was used to quantify protein concentrations.  Proteins were 
resolved by 7%, 10% or 15% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) 
membranes for Western blotting using anti-APP, BACE, occludin, iNOS, Cox-2, 
synaptophysin, PSD95, MAP2, phospho-tau (PHF-1), TNF-α, GFAP, CD68, 
CD40, CD3, CD11c, TLR2, TLR4, CD36, FATP4, pTyr, pSrc, cSrc, glut-4, CD14, 
pAKT, AKT, FAS, PPARγ, FABP4, LRP, APOE, arginase-1,DLK, LPL, VLDLR, 
adiponectin, caveolin, leptin, βIII tubulin (loading control), α-tubulin (loading 
control), GAPDH (loading control).  Antibody binding was detected with 
enhanced chemiluminescence (GE Healthcare, Piscataway, NJ, USA).  In some 
instances, antibodies were stripped from blots with 0.2 NaOH, 10 min, 25˚C, for 
antibody reprobing. Western blots were quantified using Adobe Photoshop 
software. In order to be able to compare all the samples per dietary condition for 
each antibody it was necessary to run two gels per antibody probe. To minimize 
any variability across gels, control and high fat diet samples were resolved and 
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transferred for individual antibody comparisons at the same time in the same gel 
running/transfer apparatus. The blots were incubated in the same antibody 
solution and visualized and quantified at the same time. This minimized the 
variability of across-gel comparisons. Optical density of bands were normalized 
against their respective loading controls and averaged (+/-SD). 
 
Immunohistochemistry 
Upon collection, the animals were perfused with PBS containing CaCl2 
and brain, hippocampus, visceral (pericardial/heart) fat, subcutaneous 
(abdominal/ stomach) fat, and/or intestine was collected and immersion fixed for 
24 hrs in 4% paraformaldehyde, cryoprotected through two successive 30% 
sucrose changes. Brains were embedded in gelatin and serially sectioned 
(40μm) via freezing microtome and immunostained using anti-APP, Y188, β-
amyloid, CD68, iNOS, Cox-2, or GFAP antibodies or respective secondary only 
antibodies. Subcutaneous and visceral fat tissue samples were serially 
cryosectioned (10μm) or paraffin embedded and sectioned (7μm) for 
immunostaining with anti-APP, Y188, β-amyloid, CD45 or CD68 antibodies or 
respective secondary only antibodies.  Ileum samples were serially cryosectioned 
(10μm) for immunostaining with anti-APP, OC, A11, 4G8, CD68, Cox-2, occludin, 
MAP2, CD36, pTyr, pSrc, synaptophysin, and GFAP antibodies or respective 
secondary only antibodies.  Antibody binding in brain or fat was visualized using 
Vector VIP or DAB as chromogens (Vector Laboratories, Burlingame, CA, USA). 
For double labeling, immunostained tissue was stripped of antibodies with 0.2N 
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HCl for 10 min prior to processing with the second primary antibody incubation 
and visualization steps. Images were taken using an upright Leica DM1000 
microscope and Leica DF320 digital camera system. Figures were made using 
Adobe Photoshop 7.0 software.  
 
Histological Stain 
Upon collection, the animals were perfused PBS containing CaCl2 and 
ileum of the small intestine and liver were collected and immersion fixed for 24hrs 
in 4% paraformaldehyde and cryoprotected through two successive 30% sucrose 
changes. A 1cm piece of ileum of small intestine was cut, then cut lengthwise 
and flattened for sectioning.  Ileum samples were serially cryosectioned (10μm) 
for routine histology H & E (hematoxylin and eosin) and Alcian blue stains.  Liver 
samples were paraffin embedded and sectioned (7μm) for H & E stain. For H & E 
stain, slides were rinsed in xylene three times for 1 min each, followed by 
rehydration in 2 changes of absolute alcohol for 2 min, then 95%, 80%, 70% 
alcohol for 1 min each, followed by a rinse in DH2O for 1 min.  Slides were then 
stained with Hematoxylin Regulars for 40 seconds followed by a rinse in running 
tap water for 10 dips, then differentiated with 3% acid alcohol for 2 dips, followed 
by rinse in running tap water for 10 dips.  Slides were then blued in lithium 
carbonate (1% sodium bicarbonate) solution for 3-5 dips followed by rinsing 
again in running tap water before a 1 min rinse in 70% alcohol and then 5-10 
seconds in Eosin.  Slides were dehydrated two times each for 1 min in 95% 
alcohol, 100% alcohol and xylene followed by covering with Permount (Electron 
28 
 
Microscopy Sciences).  For Alcian blue stain, slides were placed in 100% 
alcohol, 95% alcohol, 70% alcohol, and DH2O for 1 min each then mordant in 3% 
aqueous acetic acid for 1 min, 1% Alcian blue in 3% acetic acid pH 2.5 for 10 min 
followed by rinse in running water for 5-6min and rinse in DH2O.  Slides were 
counterstained in Nuclear Fast Red 0.1% (kerechtrot) for 1.5 min then rinsed in 
running water for 10 min before dehydrating in 95% alcohol, 100% alcohol and 
xylene 2 times each for 1 minute before being covered with Permount. 
 
Glucose, Triglycerides, HDL and Total Cholesterol Measurements 
Prior to collection mice were fasted for 6hrs (water only) and then glucose, 
triglycerides, HDL and total cholesterol were measured using a CardioChek 
meter (Test Medical Symptoms @ Home, Inc, Maria Stein, OH, USA) and 
corresponding strips via tail lancet.  After baseline measurements were recorded 
mice were injected intraperitoneally with 2g/kg glucose followed by 30, 60, 90, 
120 min glucose measurements. 
 
Macrophage Isolation and Stimulation 
At collection non-elicited peritoneal macrophages were rinsed from the 
peritoneal cavity with sterile PBS, counted, plated and allowed to adhere to the 
tissue culture wells for 2-3 hours in DMEM/F12 plus PSN antibiotics (0.05mg/mL 
Penicillin, 0.05mg/mL Streptomycin, 0.1mg/mL Neomycin (Gibco, Carlsbad, CA, 
USA)).  Ileum of the intestines were removed from the abdominal cavity and 
rinsed with sterile PBS inside and outside to remove residual contents.  
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Intestines were then rinse again with HBSS (8g NaCl, 0.4g KCl, 3.57g Hepes, 
0.06g Na2HPO4 x 2 H2O, 0.06 g KH2PO4 in 1 liter DH2O) and then placed in 
sterile enzyme solution (5mM Glucose, 1.5% BSA, 5mg/mL Collagenase, 20% 
FBS in HBSS), minced and placed in 37°C incubator for 30 min to allow digestion 
to occur.  Tissue was then triturated, filtered through a 70μm cell strainer, 
quenched with HBSS and spun for 4 min at full speed.  The pellet was 
resuspended in HBSS, triturated and spun for another 4 min at full speed.  The 
pellet was resuspended in DMEM/F12 plus PSN antibiotics and 400uL of 
suspended cells was plated in another 1mL of DMEM/F12 plus PSN antibiotics 
for 2-3 hours to allow adherence of macrophages. Nonadherent and non-
macrophage cells were rinsed from the wells using ice-cold DMEM/F12.  
Macrophage were then plated in DMEMF12 containing isotype negative control 
1μg/mL IgG1 (Millipore, Billerica, Massachusetts USA), APP agonist antibody 
1μg/mL 22C11 (Millipore, Billerica, Massachusetts USA), 25ng/mL LPS (Sigma) 
or 100nM Aβ1-40 or 100pM Aβ1-40 or media alone was added to the wells 
overnight for stimulation. Media was collected for ELISA and cytokine arrays. 
 
Microglia Isolation and Stimulation 
Acutely isolated microglia were collected at 22 weeks as previously 
described (Floden and Combs, 2006).  Briefly, cortices were isolated, finely 
minced and filtered through 140 and 70 um filters then gently digested with 
DNAse I and collagenase before being separated on a Percoll gradient.  The 
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microglial layer was collected, counted and used for stimulations. Microglia were 
stimulated overnight with 25ng LPS, 10µM Aβ1-40 or media alone. 
 
Intestinal Epithelial Cell Isolation and Stimulation 
 Ileum of the intestines were removed from the abdominal cavity and rinsed 
with sterile PBS inside and outside to remove residual contents.  Intestines were 
then rinse again with HBSS (8g NaCl, 0.4g KCl, 3.57g Hepes, 0.06g Na2HPO4 x 
2 H2O, 0.06 g KH2PO4 in 1 liter DH2O) and then cut longitudinally to open and 
placed in 15nM dithiothreitol (Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes 
at 37°C to remove mucus. Tissue was then further digested in HBSS + antibotics 
(0.05mg/mL Penicillin, 0.05mg/mL Streptomycin, 0.1mg/mL Neomycin (Gibco, 
Carlsbad, CA, USA)) + 10% FBS + 1.5mg collagenase (Worthington, Lakewood 
NJ, USA) and 400U dispase (Sigma-Aldrich, St. Louis, MO, USA) for 45 minutes 
at room temperature then 45 minutes at 37°C on an agitator.  Digestion was 
stopped by adding one volume of complete media (DMEMF12 + antibiotics + 
10% DHS + 20% FBS).  Cells were then spun, spent media was removed, and 
the pellet was resuspended in complete media + D-Sorbitol (Sigma-Aldrich, St. 
Louis, MO, USA) (buoyancy aid to help separate the crypts and single cells for 
the tissue pellet) and pipetted vigorously. Tissue was allowed to settle for 1 min 
and then supernatant was filtered through a 70µM cell strainer (BD Falcon, 
Franklin Lakes, NJ, USA). Filtered suspension was then spun and the pellet was 
suspended in complete media + 10mM L-glutamine (Sigma-Aldrich, St. Louis, 
MO, USA) and plated overnight. After 24 hours spent media was removed and 
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replaced with new media allowing the cells to culture for an additional 3 days 
prior to treatment. Epithelial cells were then stimulated overnight with 25ng/mL 
LPS, 10µM Aβ1-40, or media alone. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Media was collected form overnight stimulation of macrophage or 
microglia was used to quantifying secreted TNF-α according to the 
manufacturer’s protocol (R&D Systems, Minneapolis, MN, USA), secreted 
keratinocyte chemokine (KC), Regulated upon Activation, Normal T-cell 
Expressed, and Secreted (RANTES), Interleukin-6 (IL-6), Interleukin-1 beta (IL-
1β) according to the manufacturer’s protocol (R&D Systems, Minneapolis, MN, 
USA), Aβ 1-40 and Aβ 1-42 Elisa (Invitrogen, Life Technologies, Grand Island, 
NY, USA).  Stool washing samples were also diluted further by 1:5000 and 
300uL of the dilute sample was added to the IgA Elisa plate according to 
manufacturer’s protocol (Bethyl Laboratories Inc, Montgomery, TX, USA).  
Secretion was normalized to cell protein amount as determined by the Bradford 
method (Bradford, 1976b) after cells were lysed in ice cold RIPA buffer with 
protease inhibitors, sonicated, and spun to remove insoluble material. Data is the 
average (+/-SD). Tissue was weighed, lysed in RIPA buffer, sonicated, 
centrifuged, and then supernatant plated for quantifying levels of TNF-α, IL-6, IL-
10, IL-4, MCP-1, IL-1β, and adiponectin according to the manufacturer protocol 




Migration and Proliferation Assay 
After rinses following the 2-3 hours of adherence, macrophages were 
removed with ice cold dissection media and gentle trituration.  One set of 
macrophages (5,000 cells/well/96 well) had DMEM/F12 containing PSN 
antibiotics, 10% FBS and 5% horse serum added for 72hrs followed by an MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay to 
indirectly measure cellular proliferation.  The media was removed and replaced 
with 0.1mg/mL MTT for 4 hr. The precipitated formazan was dissolved in 
isopropanol and absorbance read at 560nm. Another set of macrophages (5,000 
cells/well) were resuspended in DMEM/F12 and transferred to Transwell 
permeable support inserts (3μm, Corning Inc. Corning, NY, USA) in collagen 
coated 24 well dishes containing 25ng/mL LPS to measure transmigration by 
counting the number of migrated cells after 24 hours.   
 
Prostaglandin Analysis 
PG were analyzed as previously described (Golovko and Murphy, 2008). 
Brain samples (were homogenized in 1 mL of saline and extracted with 2 mL of 
acetone containing 0.005% butylated hydroxytoluene (BHT) following with 2 mL 
of chloroform with 0.005% BHT. PGE2d4 was used as internal standard. After 
extraction, the samples were dried under a stream of nitrogen and then 
redissolved in 30 µL of acetonitrile:water (1:2 by volume). Reverse-phase LC 
electrospray ionization mass spectrometry was used for PG analysis. The PG 
were separated on a Luna C-18(2) (3 μm column, 100 A pore diameter, 150 x 2.0 
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mm) (Phenomenex, Torrance, CA, USA) with security guard cartridge system 
(Phenomenex, Torrance, CA, USA). The LC system consisted of an Agilent 1100 
series LC pump with a wellplate autosampler (Agilent Technologies, Santa Clara, 
CA). The solvent system was composed of 0.1% formic acid in water (solvent A) 
and 0.1% formic acid in acetonitrile (solvent B).  The flow rate was 0.2 mL/min. 
The separation program started with 10% of solvent B. At 2 min, the percentage 
of B was increased to 65% over 8 min, at 15 min the percentage of B was 
increased to 90% over 5 min, and at 35 min it was reduced to 10% over 2 min. 
Equilibration time between runs was 13 min. Mass spectrometry analysis was 
performed using a quadrapole mass spectrometer (API3000, Applied Biosystem, 
Foster City, CA, USA) equipped with a TurboIonSpray ionization source. Analyst 
software version 1.5.1 (Applied Biosystem, Foster City, CA, USA) was used for 
instrument control, data acquisition, and data analysis. The mass spectrometer 
was optimized in the multiple reaction-monitoring mode. The source was 
operated in negative ion electrospray mode at 450 oC, electrospray voltage was -
4250 V, nebulizer gas was 8 L/min and curtain gas was 11 L/min. Declustering 
potential, focusing potential, and entrance potential were optimized individually 
for each analyte. The quadrupole mass spectrometer was operated at unit 
resolution.   
 
Uptake for Cell Cultures 
 [1–14C]16:0, [1–14C]20:4 (n-6) and [1–14C]22:6 (n-3) were dissolved in 
ethanol and had a final specific activity of 55 nCi/nmol, 50 nCi/nmol and 51 
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nCi/nmol, respectively. Cells were incubated in serum free media containing fatty 
acid tracer (50 nCi/ml) for 5, 15 and 30 min at 37°C. Ethanol concentration in the 
medium was 0.2%. At the end of incubation, cells were washed twice with ice-
cold phosphate-buffered saline and extracted with hexane:2-propanol (3:2) and 
an aliquot of lipid extract was assayed for radioactivity using liquid scintillation 
counter.   
 
Antibody-Based Cytokine Array 
The media from stimulated macrophage or microglia was removed, or 
tissue lysed in lysis buffer and quantitated by Bradford in which 1mg per sample, 
was used to probe a 40 cytokine antibody-based membrane array according to 
the manufacturer’s protocol (Ray Biotech, Norcross, GA, USA). Optical density of 
dots were normalized against their respective positive controls and averaged (+/-
SD). 
 
Adipocyte, Adipose Tissue Macrophage, and Fibroblast Isolation and Stimulation 
 
Adipocyte cultures were generated via a modification of a prior method 
(Fernyhough et al., 2004). Subcutaneous abdominal adipose tissue was removed 
from the mice, rinsed with sterile Hanks Balanced Salt Solution (HBSS), minced 
with scissors, placed in 35mm plates and incubated for 1hr @ 37C on a rocker in 
a sterile enzyme solution (5mM glucose, 1.5% BSA, 5mg collagenase in HBSS).  
Following incubation, adipocytes were spun at 186xg for 2 min and the two layers 
were separated into separate tubes. Both the upper and the lower layer was 
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resuspened in sterile HBSS to repeat the spin, rinse was repeated two times. 
The final lower layer (stromal vascular layer) was resuspended in DMEM/F12 + 
antibiotics (0.05mg penicillin/0.05mg streptomycin/0.01mg neomycin/mL) and 
plated on 24 well plates for 3 hours.  Nonadherent and non-macrophage cells 
were rinsed from the wells using ice-cold DMEM/F12.  Macrophages were then 
plated in DMEMF12 containing 25ng LPS or 100nM Aβ 1-40 or 100pM Aβ 1-40 
or media alone was added to the wells overnight for stimulation. Media was 
collected for ELISA and cytokine arrays. The final upper (adipocyte and 
fibroblast) layer was resuspended in DMEM/F12 + 10% FBS + 5% horse serum + 
antibiotics (0.05mg penicillin/0.05mg streptomycin/0.01mg neomycin/mL).  The 
cells were added to 96 well plates, with DMEM/F12 +10% FBS +5% horse serum 
+ antibiotics. The plates were then completely filled to the brim with media, 
covered with sterile parafilm, and inverted for 2 weeks to allow floating 
adipocytes to adhere to the tissue culture treated component of the plastic wells 
and the fibroblast could adhere to the opposite side of the flask. After 2 weeks, 
the media was removed, cells were lysed or the plates were placed right-side up 
so that adipocytes were now available for stimulation or left as is for fibroblast 
use. The cells were treated with serum free DMEM/F12 and unstimulated 
(control) or stimulated for 24hr with 1µg/mL IgG1 (isotype negative control) or 
1µg/mL 22C11 (APP agonist antibody) or 100nM Aβ 1-40. After 24 hours, 
secreted LDH was measured according to the manufacture protocol for both the 
media and the cell lysates using commercial reagents (Promega, Madison WI). 
Secreted media LDH values were normalized against cellular LDH values. Media 
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was also collected for ELISA analysis quantifying secreted TNF-α according to 
the manufacturer’s protocol (R&D Systems, Minneapolis, MN). Cells were also 
fixed, stained with Oil Red O (Alfa Aesar, Ward Hill, MN, USA) and DAPI (4',6-
diamidino-2-phenylindole) (Sigma Aldrich, St. Louis, MO, USA) counterstained 
and changes in Oil Red O absorbance (510nm) normalized to DAPI absorbance 
(358/461nm) were quantified via plate reader. Experiments were repeated three 
independent times. 
 
Neuronal Isolation and Stimulation 
Pregnant dams were sacrificed by CO2 asphyxiation and cardiac 
exsanguination to isolated embryonic day 16 (E16) pups, Fetuses were removed 
from the uterus and the entire brain was removed.  Using a dissecting 
microscope under the hood, both cortices were collected and meninges were 
removed.  Cortices was minced into pieces and digested with 0.25% trypsin for 
15-20min @ 37°C. Following digestion the trypsin was neutralized by adding the 
tissue to 10mL of FBS or DMEM/F12 with 5% horse serum, 10% FBS and 
antibiotics.  The tissue was then removed from the serum or media and added to 
10mL of Neurobasal media.  Trituration was done to gently break up the tissue.  
Neurons were counted and plated accordingly for use. Neurons were stimulated 
overnight with 1µg/mL IgG1 (isotype negative control), 1µg/mL 22C11 (APP 
agonist antibody), 1.2µM BACE inhibitor (β-secretase inhibitor II) (Calbiochem, 
Billerica, MA, USA), vehicle control DMSO, or media alone. Following overnight 




For co-immunoprecipitations, tissues or cells were collected and lysed in 
ice-cold triton lysis buffer (20mM Tris, pH 7.4, 150mM NaCl, 1mM Na3VO4 
10mM NaF, 1mM EDTA, 1mM EGTA, 0.2mM phenylmethylsulfonyl fluoride, and 
1% Triton). Tissues or cells were homogenized using a teflon pestle.  
Homogenates were incubated on ice for 15 min, followed by centrifugation to 
remove insoluble material (14,000 rpm, 4 ◦C, 10 min). Homogenates were 
incubated with precipitating antibody (anti-APP or anti-CD36) (1 μg of 
antibody/mg protein lysate) for 2 h at 4 °C, followed by incubation with protein 
A/G agarose beads (Santa Cruz Biotech, Santa Cruz, CA) for 2 h at 4 °C. 
Resulting immunoprecipitates were washed three times in triton buffer and 
resolved by 10% SDS-PAGE and Western blotted as described. 
 
Caco-2 Cells 
Caco-2 cells were purchased from ATCC (Manassas, VA, USA). Caco-2 
cells were maintained in DMEMF12 (Gibco, Life Technologies, Grand Island, NY, 
USA) supplemented with 10% FBS, 5% donor horse serum (Serum Source 
International, Charlotte, NC, USA) and antibiotics (0.05mg penicillin/0.05mg 
streptomycin/0.01mg neomycin/mL) (Sigma-Aldrich, St. Louis, MO, USA). Caco-
2 cells were plated allowed to grow to confluence before removing supplemented 
media and replacing with serum free DMEMF12 with or without treatment. 
Following stimulation Caco-2 cells were used for Aβ uptake, MTT assays, ELISA, 
and Western blot analysis. 
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Caco-2 and Microglia Aβ Uptake Assay 
FITC labeled Aβ1-40 was prepared according to the manufacturer’s 
protocol (rPeptide, Bogart, GA, USA). 500nM of the peptide was added to 
confluent cells in serum free DMEM/F12 for 4 hours in the absence or presence 
of 10ng/mL LPS. The media was then removed and extraceullar peptide signal 
was quenched by rinsing cells with 0.25% trypan blue dissolved in PBS. Aβ 
uptake was quantified using a fluorescent plate reader (480 nm excitation and 
520 nm emission). 
 
Caco-2 Cell ELISA 
Caco-2 cells were incubated overnight in serum free DMEM/F12 with or 
without 10ng/mL LPS, 100nM Aβ 1-40, 1µM Aβ 1-40, or 5µM Aβ1-40. The media 
was collected for Aβ 1-40 and Aβ 1-42 (Invitrogen, Life Technologies, Grand 
Island, NY, USA), IL-8, MCP-1, MDC, IL-6, and TNFα ELISA (R&D systems, 
Minneapolis, MN, USA). The cells were lysed in using ice cold RIPA buffer with 
protease inhibitors and 50U/mL DNAse1.  To remove insoluble material cell 
lysates were sonicated and centrifuged (14,000 rpm, 4˚C, 10 min). The Bradford 
method (Bradford, 1976b) was used to quantitify protein concentrations for 







Caco-2 MTT Reduction Assay 
The MTT assay was used to determine changes in cell viability using 
3[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide (MTT, 100µg/mL) 
(M-2128) purchased from Sigma (St. Louis, MO) that we dissolved in 
DMEM/F12. Following the overnight stimulations, media was removed and the 
cells were incubated with MTT for 4 hours. The media was aspirated and the 
reduced formazan precipitate was dissolved in isopropanol. Absorbance values 
were read at 560/650nm via plate reader. 
 
Blood Collection and LAL Assay 
At the time of perfusion, blood was collected in heparinized tubes via heart 
puncture and spun at 190g~7400rpm for 10min at 4°C.  Plasma was then 
transferred to sterile centrifuge tubes which were flash frozen to be analyzed the 
following day for lipopolysaccharide (LPS) quantitation according to the Genscript 




Total stool weight was measured by placing the animals in a clean empty 
cage and collecting all stool produced over a 1hr time period.  Stool was then 
desiccated at 80°C overnight to determine dry weight.  Stool water was 





The data were analyzed by unpaired two-tailed t-test with or without Welch 
correction for unequal variance as required, by two-way repeated measures 
ANOVA with Holm-Sidak post hoc test, by two-way ANOVA with Holm-Sidak post 
hoc test, by one-way ANOVA with Holm-Sidak post hoc test or a Kruskal-Wallis 

























AMYLOID PRECURSOR PROTEIN AND PROINFLAMMATORY CHANGES 
ARE REGULATED IN BRAIN AND ADIPOSE TISSUE IN A MURINE MODEL 
OF HIGH FAT DIET-INDUCED OBESITY 
 
High fat diet feeding increased brain levels of APP and multiple pro-inflammatory 
proteins compared to control diet fed mice 
 
In order to establish the system for comparing changes in adipose tissue 
to brain, a standard high fat diet feeding paradigm was used. 24 six week old 
weight-matched male C57BL6 mice were placed on either a 21.2% by weight 
high fat diet or a 5.5% by weight control diet, ad libitum, beginning at six weeks of 
age (Table 1). Twelve animals in each group were weighed weekly for 22 weeks 
and mean (+/-SD) weight gain per group was graphed versus time (Figure 1).  By 
week five the high fat diet fed mice demonstrated a statistically significant 
increase in weight gain over the control diet fed mice (Figure 1). After 22 weeks, 
the high fat diet fed mice had on average a 217% total weight gain, whereas 
control diet fed mice had on average only a 158% total weight gain.  
To examine whether proinflammatory or degenerative changes were 
occurring in the brains of high fat diet fed animals, Western blot analysis of 
hippocampi from both groups was performed. As expected, high fat diet fed mice 
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animals (Figure 2). Although Cox-2 protein levels were not altered, we further 
examined enzyme activity and total brain prostaglandin (PG) levels (a sum of 
PGE2, PGD2, 6-ketoPGF1α, PGF2α, and thromboxane B2) were quantitated from 
animals in each diet group. Interestingly, high fat diet fed animals demonstrated a 
significant increase in brain prostaglandin levels compared to control fed animals 
indicating elevated arachidonic acid metabolism in spite of no significant change 
in protein levels of Cox-2 (Figure 2). Additionally, high fat diet feeding did not 
significantly alter phosphorylation levels of tau protein (Lang et al., 1992) as 
assessed using the PHF-1 antibody (Figure 2). These data demonstrate that high 
fat diet feeding stimulates an increase in APP protein levels in the brain which 
correlates with an increased level of gliosis and elevated prostaglandin levels. 
This supports the notion that the chronic inflammatory changes associated with 
peripheral tissue during diet-induced obesity extend into the brain. Moreover, 
these changes are consistent to some degree with those that are observed 
during Alzheimer’s disease. 
 
Proinflammatory protein immunoreactivity increased in neurons in brains from 
high fat diet versus control fed mice 
 
Although the Western analysis demonstrated significant protein changes 
in high fat diet fed mice compared to controls, the cellular identity of those 
proteins was unknown. Understanding the cellular contribution was of particular 
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animals in each diet are shown. Optical densities of the Western blotted 
hippocampal proteins (APP, CD68, iNOS, Cox-2, GFAP, synaptophysin, PSD95, 
and phosphor-tau) from the control and high fat diet Western blots were 
normalized against their respective averaged O.D. values of combined α-
tubulin+βIII tubulin+actin loading controls (+/- SD) from 5 animals for each diet. 
Total brain PG levels were quantitated as a sum of PGE2, PGD2, 6-ketoPGF1α, 
PGF2α, and thromboxane B2 in each diet group. *P<0.05 and **P<0.01.  
 
In order to determine which cells may be responsible for the changes in 
protein levels, immunohistochemistry was performed from the collected 
hippocampi. In agreement with the fact that the majority of APP is expressed by 
neurons in the brain (Bendotti et al., 1988) both high fat and control diet fed mice 
displayed neuronal immunoreactivity for APP with a diet-induced increase in 
immunoreactivity in the high fat diet fed mice (Figure 3). To examine whether 
APP was increasingly processed or deposited as the proteolytic fragment, beta 
amyloid (Aβ), brain sections were also immunostained using an anti-mouse Aβ 
antibody. However, there was no obvious change in intensity or distribution of Aβ 
immunoreactivity in the different diet fed animals (Figure 3). Cox-2, iNOS, and 
CD68 histologic analysis demonstrated what appeared to be elevated 
immunoreactivity for each (Figure 3) although this did not reach the level of 
statistical significance via Western blot analysis (Figure 2). Interestingly, the 
immunoreactivity for both Cox-2 and iNOS in high fat diet fed animals appeared 
within neurons as opposed to glia (Figure 3). Although, the difference in 
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immunoreactivity for reactive microglia (CD68) was modest, there was a clear 
increase in astrocyte GFAP immunoreactivity in the high fat diet fed animals 
compared to controls demonstrating that at least an astrogliosis was occurring 
(Figure 3). These data demonstrated that high fat diet feeding induced a reactive 
gliosis in the brain. However, since the Western blot analysis detected increased 
protein levels of APP within neurons, the proinflammatory changes were not 
limited to any particular cell type in the brain but instead appeared to include a 
multi-cellular response.  
In spite of the fact that microglia and astrocytes demonstrated 
immunoreactivity for typical activation markers, CD68 and GFAP respectively, 
this was not necessarily a reflection of a contribution to any proinflammatory 
changes that were occurring. As a means of assessing this, microglia were 
further examined based upon our prior experience with isolating these cells from 
adult animals (Floden and Combs, 2006). For comparison, microglial secreted 
TNF-α levels were compared to values derived from resting peritoneal 
macrophage as a positive control. In general microglia isolated from the 22 week 
old control fed animals secreted far less TNF-α when compared to their 
peripheral cell counterparts (Figure 4). However, microglia from high fat diet fed 
mice secreted significantly more TNF-α than the control diet fed animals (Figure 
4). This was entirely consistent with the subtle increase in CD68 
immunoreactivity observed even though quantified Western blot analysis 
revealed no significant difference in CD68 protein levels in the brains of high fat 
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ad libitum, a control (5.5% fat/weight) or high fat (21.2% fat/weight) diet for 22 
weeks. Microglia were isolated from brains for comparison to non-elicited 
peritoneal macrophage. Isolated microglia or macrophage from control and high 
fat diet fed mice were plated overnight in serum free DMEM/F12 media and 
secreted TNF-α levels were quantified by commercial ELISA. Data is the average 
(+/-SD) of 12 animals/condition. *P<0.05. 
 
High fat diet feeding increased APP and TNF-α protein levels compared to 
control diet fed mice in both subcutaneous and visceral fat depots 
 
Based upon the changes observed in the brain, adipose tissue was next 
examined to determine whether similar changes in proinflammatory protein 
expression occurred in the periphery. Because visceral and subcutaneous fat 
depots can have altered protein expression changes during diet-induced obesity 
(Borst and Conover, 2005, Poussin et al., 2008, Matsubara et al., 2009, Ibrahim, 
2010) both types of adipose reservoirs were assessed. To begin comparing 
protein changes between brain and adipose tissue, Western blot analysis was 
again performed. Subcutaneous abdominal fat and visceral pericardial fat were 
examined as representative samples of two distinct fat depots. Precisely as 
observed in the brain, high fat diet fed mice demonstrated a significant increase 
in APP protein levels in both fat depots over control diet fed mice (Figure 5). To 
again assess if there was a proinflammatory change, the two proinflammatory 
protein markers quantified from brain, iNOS and Cox-2, were next examined in 
the fat depots. Consistently, the diets demonstrated no difference in either iNOS 
or Cox-2 protein levels in either type of adipose tissue (Figure 5). However, 
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based upon the fact that microglial-secreted TNF-α levels were increased in high 
fat diet fed mice and TNF-α elevations are a well characterized change in 
adipose tissue from obese individuals (Hotamisligil et al., 1995, Kern et al., 1995) 
or animals (Hotamisligil et al., 1993), we next quantified TNF-α protein levels. 
Similar to the changes observed from brain microglia, both visceral and 
subcutaneous fat depots demonstrated increased TNF-α levels compared to pair 
fed controls (Figure 5). These data demonstrate that although there were no 
significant differences between visceral and subcutaneous fat depots, the overall 
proinflammatory changes were consistent between adipose tissue and brain 
during high fat diet feeding. In particular, the proinflammatory proteins, Cox-2 and 
iNOS, were not significantly increased in either the brain or adipose tissue in 
spite of the observed elevation in TNF-α from both tissue types. Perhaps the 
most interesting observation was that APP levels increased in both brain and 
adipose tissue. This demonstrated that a coordinated, increased expression of 
APP occurred in the brain and adipose tissue upon diet-induced obesity along 
with acquisition of proinflammatory tissue phenotypes.  
 
Adipose tissue APP immunoreactivity from high fat diet fed animals localized to 
adipocytes and macrophage 
 
Although brain changes in APP were determined to be neuronally 
localized it was not likely that the increased APP levels in adipose tissue were 
also neuronal. Therefore, to identify the cellular origin of the increased APP 
levels in high fat diet fed adipose tissue immunohistochemistry was again 
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respective GAPDH loading controls and averaged (+/- SD) from 12 animals per 
each condition. *P<0.05, **P<0.01 
 
Similar to the observations found during brain analysis, immunostaining of 
the two different adipose depots with anti-mouse Aβ antibody did not 
demonstrate a robust increase in immunoreactivity in high fat diet fed animals 
nor, any plaque-type patterns (Figure 6A). Although prior work has demonstrated 
increased adipocyte APP immunoreactivity in samples from obese humans, it 
was possible that the increased APP immunoreactivity observed in our animal 
paradigm was also localized to macrophage. Our prior work has shown that 
monocytic lineage cells express APP and levels increase upon differentiation and 
activation (Sondag and Combs, 2004a, 2006b, 2010a). Moreover, a variety of 
studies have demonstrated that increased macrophage infiltration into adipose 
tissue occurs during diet-induced obesity (Weisberg et al., 2003, Kanda et al., 
2006, Coenen et al., 2007). Interestingly, both subcutaneous and visceral 
adipose tissue demonstrated increased immunoreactivity for CD68 to identify 
macrophage (Figure 6). Importantly, this increase in CD68 positive adipose 
tissue macrophage correlated precisely with the slight increase in CD68 positive 
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fat/weight) or high fat (21.2% fat/weight) diet for 22 weeks. Subcutaneous 
abdominal and visceral pericardial adipose tissue samples were collected, 
immersion fixed, serially sectioned and immunostained using anti-CD68 antibody 
and binding visualized using DAB as the chromogen. For double-labeling, tissue 
sections were stripped using 0.2N HCl and subsequently immunostained using 
anti-APP antibody and binding visualized using Vector VIP as the chromogen. A 
representative image from 12 animals per condition is shown. The brown arrow 
indicates CD68 immunoreactivity, the red arrow indicates APP immunoreactivity 
and the black arrow indicates double-label of CD68 and APP antibody binding. 
 
The APP agonist antibody, 22C11, increased macrophage cytokine production 
but had no effect on viability, lipid storage/accumulation, or TNF-α secretion in 
adipocytes 
 
To begin examining whether increased expression of APP had any role in 
altering the phenotype of macrophage or adipocytes, primary murine cultures 
were generated from non-elicited peritoneal macrophage and subcutaneous 
adipocytes and then stimulated using an agonist antibody for APP (Sondag and 
Combs, 2006b).  We first stimulated peritoneal macrophage with 1μg/mL IgG1 
(isotype control) or 22C11 (APP agonist antibody) and measured cytokine 
secretion (Figure 8).  The APP agonist, 22C11, stimulated a significant increase 
in secretion of granulocyte-macrophage colony stimulating factor (GM-CSF) 
which reportedly increases the production of macrophages (Burgess et al., 
1977).  This was consistent with the increase in immunoreactivity for CD68 
(macrophages) in both adipose tissue depots during high fat diet-induced 
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obesity.  Stimulation with 22C11 also significantly increased secreted levels of 
IFNγ, a macrophage-activating factor, that plays a critical role in 
immunostimulatory and immunomodulatory effects (Wallet et al., Schroder et al., 
2006). In contrast, 22C11 stimulation significantly increased secreted IL-13 levels 
which is reportedly responsible for down-regulation of macrophage activity and 
thereby inhibits the production of pro-inflammatory cytokines and chemokines 
(Doherty et al., 1993). Although these findings do not demonstrate precisely what 
secretory changes APP-overexpressing macrophage may be exhibiting in situ 
during diet-induced obesity, they do provide clear evidence that APP stimulated 
changes in macrophage phenotype are complex with alterations in both 
proinflammatory and anti-inflammatory secretion that will need to be further 
resolved in vivo in the diet-induced obesity model.  
To assess any effect of APP on adipocyte phenotype, we next stimulated 
primary murine abdominal subcutaneous fat derived-adipocytes with 1μg/mL 
IgG1 or 22C11 antibodies. Unlike the macrophage studies, agonist antibody 
stimulation of adipocytes did not produce any obvious change in phenotype. 
There was no significant toxicity of the 22C11 or IgG1 stimulated adipocytes as 
assessed by LDH release (Figure 9A).  Since TNFα levels were increased under 
diet-induced obesity conditions in both adipose tissue depots, TNFα secretion 
was measured from APP stimulated adipocytes (Figure 9B).  However, the APP 
agonist, 22C11, did not stimulate a significant change in TNFα secretion. To 
assess a differentiative phenotype, stimulated adipocytes were stained and 
quantified using Oil Red O (Figure 9C and 9D) to examine lipid 
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storage/accumulation. APP stimulation with 22C11 produced no changes in Oil 
Red O staining. Although a minor subset of all the possible changes in adipocyte 
phenotype was examined, the data thus far indicates that viability, 
proinflammatory secretion, and differentiation state are not affected by APP 
signaling. This suggests that further investigation is needed to fully understand 
the role of APP in adipocyte biology both basally and during instances of 
increased APP expression such as that which occurs during diet-induced obesity. 
This data demonstrates that both brains and adipose tissue from wild type 
mice had elevated APP levels localizing to neurons and macrophage/adipocytes, 
respectively.  Adipose tissue and brain microglia from high fat diet fed wild type 
mice demonstrated increased TNFα and microglial/macrophage activation. 
Finally, APP agonist antibody stimulation of wild type macrophage cultures 











































stimulated with 1μg/mL IgG1 or 1μg/mL 22C11 APP agonist antibody overnight 
and the media was removed and used according in a commercial antibody-based 
40 cytokine antibody array. A representative dot blot per each condition is shown. 
The optical densities of individual cytokine detection spots were normalized 
against their respective positive controls per blot and averaged (+/-SD) and 
graphed from 5 animals in each group. Data were analyzed via unpaired two-


































































released into the media normalized against cellular LDH was quantified to assess 
changes in cell viability upon APP stimulation. (B) Changes in secreted TNFα 
levels were also quantified from the media as a result of APP stimulation. (C) 
Cells were also fixed, stained with Oil Red O and DAPI counterstain and changes 
in Oil Red O absorbance (510nm) normalized to DAPI absorbance (358/461nm) 
were quantified via plate reader. (D) Representative images of Oil Red O and 
cresyl violet counterstained adipocytes are shown following 24 hr IgG1 and 
22C11 stimulation. Data are shown as mean (+/-SD) and are representative of 



















APP REGULATES BRAIN AND ADIPOSE CHANGES IN HIGH FAT DIET FED 
MICE 
 
Based upon our observations that increased APP immunoreactivity 
occurred in both brains and adipose tissue with high fat diet feeding and APP 
modulated the phenotype of peritoneal macrophages, we predicted APP would 
have a role in the cellular differentiation and inflammatory changes that are 
produced in adipose tissue but also brain during high fat diet induced obesity. To 
examine this hypothesis we compared wild type and APP-/- mice placed on 
control and high fat diets with the expectation that APP-/- mice would have 
attenuated weight gain, cytokine production, and macrophage/microglial 
activation basally and on a high fat diet compared to wild type mice. 
 
APP-/- mice gained significantly less weight than wild type mice fed a high fat diet 
Our first goal was to determine whether APP was required for weight gain 
due to high fat diet feeding. To assess comparative changes between wild type 
(C57BL6) and APP-/-mice, we placed 10-11, 6 week old animals from each strain 
on a 5.5% by weight control diet or a 21.2% by weight high fat diet, ad libitum, for 
22 weeks.  Five to six animals in each group were weighed weekly and mean (+/-
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SD) weight gain per group was graphed versus time (Figure 10A).  There was a 
significant difference in mean starting weight between wild type and APP-/- mice 
consistent with their smaller stature (Figure 10A).  Therefore to accurately 
compare weight gain between groups we normalized weight per week to the 
initial starting weight of each respective mouse (Figure 10B).  Wild type mice on 
high fat diet showed significantly increased weight gain vs. APP-/- mice on control 
or high fat diets after 2 weeks.  After 3 weeks of feeding, wild type mice on the 
high fat diet also demonstrated significantly increased weight gain over their wild 
type counterparts on control diet.  On the other hand, after 18 weeks on a high 
fat diet, APP-/- mice gained significantly more weight than the APP-/- mice on 
control diet. To assess whether the differences in weight gain were due to food 
intake we weighed the food weight eaten by all groups during weeks 13-17.  
Since actual food weight eaten each week would not be an accurate 
measurement due to differences in animal weight, the food weight eaten by each 
animal was divided by its weight then averaged to determine the weight of food 
eaten, per animal body weight, per group (Figure 10C).  Both genotypes ate 
significantly more control diet per body weight compared to high fat diet. In spite 
of the attenuated weight gain, APP-/- mice ate significantly more food per body 
weight of either diet type compared to wild type mice.  
In order to validate that the differences in weight gain were a result of 
changes in adipose tissue mass, total visceral (gonadal and perirenal) fat weight 
was measured between groups at the termination of the feeding paradigm 
following animal collection (Figure 10D & 10E). Two different visceral fat depots 
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were measured in these studies as visceral fat alone has been shown to be 
responsible for the metabolic consequences of obesity (Bjorntorp and Rosmond, 
1999, Frayn, 2000, Wajchenberg, 2000, Thorne et al., 2002, Rodriguez et al., 
2007). Both gonadal and perirenal fat depot weight of wild type mice on a high fat 
diet was increased compared to their control diet counterparts (Figure 10D & 
10E).  Gonadal but not perirenal fat depot weight of APP-/- mice on the high fat 
diet was also significantly increased compared to their control diet counterpart s 
(Figure 10E). This occurred  in spite of the fact that both perirenal and 
perigonadal adipose tissue from APP-/- mice on either diet were significantly less 
than their respective control diet wild type groups (Figure 10D & 10E). This 
overall decrease in adipose tissue mass was consistent with the attenuated 
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Measurement of fasting blood glucose, triglycerides, HDL and total cholesterol 
levels from wild type and APP-/- mice fed control and high fat diets 
 
Based upon the diminished weight gain of the high fat diet fed APP-/- mice, 
we predicted that these animals would also have attenuated changes in plasma 
levels of total cholesterol, triglycerides, and HDL cholesterol as well as glucose 
tolerance compared to wild type mice on the high fat diet. Mice in both groups 
were fasted for 6 hours (water only) and levels of these metabolic parameters 
were measured (Figure 11).  Glucose tolerance tests comparing the four groups 
demonstrated more efficient glucose uptake in control diet fed APP-/- mice 
compared to their respective wild type controls with levels returning to baseline in 
the APP-/- mice by 120 minutes post glucose injection (Figure 11A & 11B). 
However, both genotypes displayed impaired glucose clearance on high fat diet 
feeding demonstrating that changes in glucose sensitivity existed in the APP-/- 
mice in spite of their attenuated weight gain (Figure 11B and 11D).  As a further 
comparison, triglycerides, HDL and total cholesterol levels were also quantified 
from the animals. The APP-/- mice on high fat diet did not display the increase in 
total cholesterol levels observed in the wild type mice fed high fat diet correlating 
again with the attenuated weight gain and adipose tissue mass in this group 
(Figure 11F).  
Attenuated adipose tissue hypertrophy and attenuated total cholesterol 
levels in the APP-/- mice fed the high fat diet suggested that, in addition to the 
inflammatory changes we predicted in these mice, there might also be 
differences in adipocyte behavior and fatty acid metabolism or uptake. In order to 
further examine the possibility that a problem with fatty acid metabolism, storage, 
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or uptake might exist in these mice we examined the liver of high fat fed mice 
since diet induced obesity is characterized by robust lipid accumulation in the 
liver.  H & E staining of the livers from these mice revealed no histological 
differences between the two strains on control diet. However although high fat 
diet feeding resulted in a severe fatty change in the wild type mice, only a mild or 
moderate fatty change was observed in the  APP-/- mice (Figure 12). This 
provided further evidence that impairment of lipid metabolism, uptake, or storage 
may be occurring in these animals in a fashion that is dependent upon 




































cholesterol, total cholesterol and glucose were measured using a CardioChek 
meter (Test Medical Symptoms @ Home, Inc, Maria Stein, OH, USA) and 
corresponding strips via tail lancet. After baseline measurements were recorded 
mice were injected intraperitoneally with 2g/kg glucose followed by 30, 60, 90, 
120 min glucose measurements. Data are expressed as mean +/- SD (n = 5 or 6) 
*P<0.05, **P<0.01, ***P<0.001.  (A) Wild type mice on high fat diet, (B) Wild type 
mice on control diet, (C) APP-/- mice on high fat diet, (D) APP-/- mice on control 
diet.  (E) Combined four graphs (A-D). (E) 30 min **P<0.01 wild type on high fat 
diet vs. wild type on control diet and APP-/- on both diets; 60 min and 90min 
**P<0.01 wild type high on fat diet vs. wild type on control diet and APP-/- on high 
fat diet; 60min and 90 min +P<0.05 APP-/- mice on control diet vs APP-/- mice on 
high fat diet and wild type mice on control diet; 120 min ##P<0.01 APP-/- mice on 
high fat diet vs APP-/- mice on control diet and wild type mice on either diet. (F) 































collected, immersion fixed, sectioned, and stained using H&E. Representative 
images from 5-6 animals per condition are shown. The spectrum of lipid 
accumulation in APP-/- livers from mild to moderate are both shown in contrast to 
the typical severe accumulation observed in wild type livers. 
 
Increased inflammatory response in the fat depots of APP-/- mice compared to 
wild type mice fed control and high fat diets 
 
Several observations made from the high fat diet fed APP-/- mice supported the 
possibility that some APP-dependent regulatory mechanism of lipid metabolism 
was impaired in these animals. However, we had not yet determined whether the 
predicted changes in macrophage activation or infiltration had occurred in these 
animals as well. In order to quantify changes in immune parameters, specific 
ELISAs were selected to broadly scan for changes in each group. Levels of 
proinflammatory markers, TNF-α, IL-1β, IL-6, and monocyte chemotactic protein 
1 (MCP-1) as well as anti-inflammatory markers, IL-10 and IL-4, and the glucose 
and fatty acid oxidation marker, adiponectin, were all quantified from perirenal, 
gonadal, and subcutaneous fat depots (Figure 13). Surprisingly, in spite of the 
smaller adipose tissue mass, APP-/- mice fed a control diet demonstrated 
increased TNF-α, IL-10, IL-1, IL-1β, and MCP-1 levels in perirenal and gonadal 
fat depots compared to wild type mice fed a control diet (Figure 13).  APP-/- mice 
fed a high fat diet had significantly higher levels of IL-6 and IL-4 but decreased 
MCP-1 only in gonadal fat compared to high fat diet fed wild type mice. Control 
diet fed APP-/- mice compared to control diet fed wild type mice had increased 
levels of adiponectin in the perirenal fat with decreased levels in the 
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subcutaneous fat (Figure 13). This data demonstrated two critical observations. 
First, lack of APP clearly alters immune parameters in adipose tissue both on 
mice fed a regular or a high fat diet. Second, the role of APP in regulating any 
particular adipose tissue inflammatory phenotype appears quite complex with 
differences between the adipose tissue depots. These immune changes may or 
may not have been related to the attenuated weight gain observed from the   



































control and high fat diet for 22 weeks and perirenal,gonadal, and subcutaneous 
adipose tissue was collected to quantify IL-6, TNFα, IL-10, IL-4, IL-1β, MCP-1, 
and adiponectin levels via ELISA. Data are expressed as mean +/- SD (n = 5 or 
6), *P<0.05.  
 
Multiple protein markers of differentiation and activation differed in gonadal and 
perirenal fat depots of wild type and APP-/- mice fed high fat versus control diets 
 
In order to better understand the differences in wild type and APP-/- 
adipose tissue that were observed, protein differences in visceral depots were 
assessed for changes in markers of differentiation or activation for both 
adipocytes and macrophages. Western blot analysis of gonadal fat tissue 
following the 22 weeks of diet feeding demonstrated, as expected, elevated APP 
levels in wild type mice compared to their control diet counterparts (Figure 14). 
However, high fat diet feeding did not alter any protein marker level in gonadal 
adipose tissue from wild type mice. On the other hand, APP-/- mice fed the high 
fat diet demonstrated significantly elevated gonadal adipose tissue levels of: an 
adipocyte differentiation marker, peroxisome proliferation activated receptor  
(PPARγ); fatty acid synthase (FAS) which catalyzes the synthesis of palmitate; 
fatty acid binding protein 4 (FABP4) a fatty acid carrier protein; lipoprotein 
receptor protein (LRP) which is involved in lipid homeostatis and clearance of 
apoptotic cells; arginase-1, an M2 phenotype macrophage marker; and 
adiponectin, a protein responsible for glucose regulation and fatty acid 
breakdown; compared to control diet fed APP-/- mice (Figure 14).  In fact, it 
appeared that control diet APP-/- gonadal adipose tissue was already significantly 
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different from wild type mice fed the control diet. Several protein levels were 
increased in the APP-/- tissue. Specifically, APP-/- gonadal fat had significantly 
higher levels of: cluster of differentiation 36 (CD36) which plays a role in fatty 
acid uptake and serves as a scavenger receptor; lipoprotein lipase (LPL) which 
hydrolyzes triglycerides in lipoproteins; delta like protein (DLK or Pref-1) is 
involved with differentiation of pre-adipocytes into adipocytes; toll like receptor 2 
and 4 (TLR2 & TLR4) which are pattern recognition receptors involved in 
activating inflammatory signaling cascades; phospho-Akt (pAKT) which controls 
survival and apoptosis and is involved in insulin receptor signaling; caveolin 
which is involved in endocytosis; very-low-density-lipoprotein receptor (VLDLR) 
regulates cholesterol uptake and metabolism of triacylglycerol-rich lipoproteins; 
arginase-1; and adiponectin (Figure 14).  Although the high fat feeding did not 
appear to alter the wild type gonadal adipose protein levels, The APP-/- mice fed 
the high fat diet significantly increased several protein levels. These increases 
coupled with the existing basal elevations demonstrated a plethora of changes 
above the high fat diet fed wild type mice. Specifically, the following protein 
markers were all elevated in APP-/- high fat diet fed gonadal adipose tissue: 
cluster of differentiation 14 (CD14) a co-receptor along with TLR4 for the 
detection of lipopolysaccharide; cluster of differentiation 68 (CD68) which is a M1 
macrophage marker; glucose transporter type 4 (glut-4) which is the insulin-
regulated glucose transporter; in addition to PPARγ, FAS, DLK, FABP4, TLR2, 




















































































quantified normalizing to actin as a loading control. Data are expressed as mean 
+/- SD (n= 5 or 6) *P<0.05, **P<0.01, ***P<0.001. 
Although the differences on control and high fat diet were dramatic in 
gonadal fat, we appreciate that not all adipose tissue depots behave similarly. 
Therefore, we quantified protein changes in another visceral adipose tissue 
depot, perirenal fat. In contrast to the gonadal fat, wild type mice fed the high fat 
diet did show significant increases in several proteins. Wild type mice fed a high 
fat diet had elevated Apolipoprotein E (APOE) a component of chylomicron and 
intermediate-density lipoproteins that is essential for triglyceride catabolism; as 
well as APP, PPARγ, CD36, FAS, LPL, DLK, CD14, TLR2, CD68, arginase-1, 
and adiponectin compared to the wild type mice fed control diet (Figure 15).  Also 
unlike gonadal adipose tissue, the high fat diet fed APP-/- perirenal adipose tissue 
did not display all of the increases. APP-/- perirenal adipose tissue from mice fed 
high fat diet demonstrated only decreased LPL compared to APP-/- mice fed the 
control diet (Figure 15). Nevertheless, similar to gonadal adipose tissue, perirenal 
adipose tissue from APP-/- mice on control diet still demonstrated some 
significant increases compared to wild type mice fed control diet. APP-/- perirenal 
adipose tissue demonstrated increased FAS, FABP4 and adiponectin protein 
levels compared to wild type mice fed control diet (Figure 15).  The data 
demonstrate that not only APP but also diet regulates each depot discreetly. 
Based upon our earlier work, we expected the increase in APP protein 
levels in wild type tissue to be localized primarily to macrophage and the 
changes in APP-/- compared to wild type tissue to be a reflection of diminished 
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macrophage infiltration coupled with a particular activation phenotype. Therefore, 
immunostaining of the fat depots was performed using an anti-CD68 antibody to 
detect macrophage following the 22 weeks of high-fat diet feeding (Figure 16A & 
16B). Unexpectedly, APP-/- mice demonstrated robust reactive macrophage 
immunoreactivity even without high fat diet-feeding (Figure 16A & 16B) which 
was entirely consistent with the elevated proinflammatory cytokine levels in the 
APP-/- adipose tissue (Figure 13). Even more interesting was the fact that APP-/- 
adipocytes basally demonstrated a very obvious decrease in cell volume in 
animals fed a control diet (Figure 16A & 16B). As demonstrated previously, APP 




















































































































































binding visualized using Vector VIP as the chromogen. Representative images 
from 5-6 animals per condition are shown. (C) Gonadal and perirenal adipose 
tissue samples were immunostained using anti-CD68 antibody with FITC-
conjugated secondary antibody and anti-APP antibody with texas red-conjugated 
secondary antibody. A representative gonadal fat image from 6 animals per 
condition is shown. 
 
Cytokine secretion differed from APP-/- and wild type peritoneal, intestinal, and 
adipose tissue macrophages isolated from mice fed control and high fat diets 
 
Based upon the fact that the majority of APP immunoreactivity localized to 
macrophages in wild type adipose tissue, it was logical to assume that many of 
the changes observed thus far in APP-/- mice and tissue were a consequence of 
loss of macrophage APP expression. In order to better define what role APP or 
its metabolites may have in regulating macrophage behavior, we isolated resting 
peritoneal macrophages from the control and high fat diet mice and stimulated 
them with or without a typical activating ligand, the endotoxin lipopolysaccharide 
(LPS), or an APP secreted metabolite, Aβ 1-40, to ask whether loss of APP or 
loss of stimulation from an APP metabolite induced a basal or activated 
phenotype change in wild type vs. APP-/- cells (Figure 17). We again quantified 
levels of TNF-α, IL-6, IL-10, IL-4, IL-1β, MCP-1, adiponectin as had been done in 
the adipose tissue depots. Unlike the findings made from adipose tissue, 
nonstimulated APP-/- macrophages from control diet fed animals did not secrete 
higher levels of either molecule compared to wild type cells isolated from control 
diet fed mice. However, LPS stimulation of control diet fed APP-/- macrophage did 
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demonstrate significantly increased secretion of IL-6, TNF, IL-10 and IL-1 
compared to no changes in control diet wild type macrophages. This was entirely 
consistent with the low level of increased endotoxemia we had observed in the 
APP-/- mice suggesting that the elevated cytokine levels in APP-/- control diet fed 
mice may be due to macrophage hyperreactivity to LPS stimulation (Puig et al., 
2012). Interestingly, control diet wild type and APP-/- macrophages responded to 
A stimulation with single cytokine level changes in typically described anti-
inflammatory cytokines. Wild type cells demonstrated a significant increase in IL-
4 levels while APP-/- cells had elevated IL-10.  Consistent with the fact that high 
fat diet feeding increases proinflammatory change, wild type cells isolated from 
high fat diet fed mice demonstrated increased secretion of multiple cytokines 
following LPS and A stimulation. However, high fat fed APP-/- macrophages only 
increased secretion of anti-inflammatory cytokines IL-4 and IL-10 upon LPS 
stimulation compared to their control diet cell counterparts.  
Although peritoneal macrophages clearly differed between wild type and   
APP-/- cells, their behavior did not completely mirror observations obtained from 
the tissue. One possibility is, of course, the fact that in vitro isolated cells can not 
accurately model all aspects of the complex environment or phenotype that 
occurs in vivo. However, another possibility is simply that peritoneal 
macrophages differ from other macrophages. Therefore, adipose tissue 
macrophages were isolated for comparison. Due to limitations in number and 
viability, only control diet fed macrophages from subcutaneous adipose tissue 
were compared with the expectation that their behavior would correlate best with 
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findings from subcutaneous adipose tissue. Cells from APP-/- and wild type mice 
were again stimulated with or without LPS or Aβ 1-40 (Figure 18). Adipose tissue 
macrophages clearly differed from their peritoneal counterparts demonstrated by 
the fact that APP-/- cells lacked the hyperresponsiveness to LPS stimulation. 
Indeed, the APP-/- cells were not responsive to either LPS or A and the wild type 
cells only responded to LPS with elevated TNF levels. In addition, the secretory 
pattern from the adipose tissue macrophage did not correlate with the changes 
observed from subcutaneous control diet tissues. That is, there was no difference 
in adiponectin levels between APP-/- and wild type adipose tissue macrophage. 
These data suggest, again, that wild type and APP-/- macrophages have unique 
phenotypes that are dependent upon their tissue of origin. As an additional 
assessment of tissue specific differences in macrophages another distinct pool of 
cells, intestinal macrophage, were isolated from wild type and APP-/- cells on 
control diet simply to compare basal and stimulated secretion for each of the 
proteins, IL-4, IL-6, IL-1, TNF, IL-10, MCP-1, and adiponectin (Figure 19). 
Again, these cells displayed unique secretory profiles from either peritoneal or 
adipose macrophage. Neither genotype was responsive to either LPS or A 
stimulation with APP-/- cells having basally elevated levels for nearly all of the 
proteins. This elevation is again, however, consistent with the low level of 
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Differences in various protein marker levels characterized wild type vs. APP-/- 
macrophages 
 
Based upon the cytokine secretion differences between peritoneal, 
intestinal, and adipose macrophages, additional peritoneal macrophages from 
APP-/- and wild type mice were again collected for in vitro stimulation with or 
without LPS to determine whether additional protein differences could be 
identified to better characterize the phenotypes between the cells types (Figure 
20). With the caveat that the changes were likely unique to only this subtype of 
macrophage, peritoneal macrophages were used in these experiments as 
adipose tissue macrophage numbers were too limited for these types of analysis. 
Nonstimulated APP-/- peritoneal macrophages demonstrated several differences 
from nonstimulated wild type cells. APP-/- cells had decreased PPARγ, CD36, 
arginase-1 and CD86 levels. Stimulation with LPS decreased PPARγ, arginase-1 
and CD86 levels in wild type cells compared to their unstimulated controls while 
APP-/- cells increased CD36 levels compared to their controls. This again 
indicated fundamental differences basally and upon stimulation between the two 
genotypes. To more fully assess secretory profile differences in the macrophages 
media from stimulated macrophages was analyzed by an antibody anti-cytokine 
array (Figure 20C).  Wild type macrophages stimulated with LPS had increased 
secretion of GCSF, IL-6, and KC with decreased secretion of GM-CSF, INFγ, and 
IL-13 (Figure 20C).  Whereas APP-/- macrophages stimulated with LPS also had 
increased GCSF, LPS stimulation in these cells also increased TIMP-1 secretion 
compared to basal levels of APP-/- macrophages along with IL-1α compared to 






































































as mean +/- SD (n = 5), *P<0.05, **P,0.01 to compare differences between 
strain. +P<0.05, ++P<0.01, +++P<0.001 to compare difference between stimulated 
with LPS and unstimulated. 
 
Adipocytes from wild type and APP-/- cells demonstrated altered cytokine 
secretion and protein expression 
 
Although the macrophages had clear differences between phenotypes we 
appreciated that adipocytes also express APP and the differences in weight gain, 
and adipose tissue hypertrophy and lipid accumulation in the liver might be due 
to altered lipid uptake, storage, or metabolism as well. To begin addressing any 
changes in APP-/- adipocytes that might help explain the tissue or animal 
phenotype differences subcutaneous adipocytes were isolated for comparison. 
Again, due to limitations in viability and numbers only subcutaneous cells were 
examined. APP-/- adipocytes had increased levels of the differentiation marker 
(PPARγ), fatty acid synthase (FAS) which catalyzes the synthesis of palmitate, 
the pre-adipocyte marker (Pref-1/Dlk), the cluster of differentiation 14 (CD14) a 
co-receptor along with TLR4 for the detection of lipopolysaccharide, and 
adiponectin the glucose regulation and fatty acid breakdown marker, as 
compared to wild type adipocytes (Figure 21). Since APP-/- cells demonstrated an 
increase in fatty acid markers they were then used to determine whether this 
correlated with a difference in fatty acid uptake. To assess this, palmitic acid 
uptake was quantified in both genotype cells to find no significant difference in 
the ability of either genotype cell to take up this fatty acid (Figure 21C). This data 
indicate that although the APP-/- and wild type adipocytes had similar abilities for 
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fatty acid uptake there were several differentiation markers that differed between 
the two. This indicated that changes in cellular phenotype were likely not limited 
to macrophage in vivo in adipose tissue in spite of the low level of adipocyte APP 
expression. Since a major adipocyte fatty acid uptake protein, CD36, was 
increased in the gonadal adipose tissue of APP-/- mice, it was possible that APP 
was directly involved in regulating fatty acid uptake. To determine whether APP 
is part of a multi-protein complex with CD36, co-immunoprecipitation pull-down 
experiments from cultured adipocytes were performed. These demonstrated that 
APP and CD36 were not part of a multi-protein complex (Figure 21C) implying 
that loss of APP in the adipocytes does not alter the fatty acid uptake ability of 
CD36.  
To answer the question of whether APP also served as a receptor on 
adipocytes, adipocytes cultures were stimulated with the APP agonist antibody, 
22C11, as we had previously shown this antibody to directly stimulate the 
proinflammatory receptor actions of APP on monocyte/macrophage cells 
(Sondag 2004). Morphologically, cells from either genotype appeared similar 
(Figure 22C). Furthermore, stimulation with agonist antibody had no ability to 
alter levels of any protein marker compared to isotype matched negative control 
antibody stimulation (Figure 22A & 22B). However, quantitation of secreted 
cytokines from the media of the cultured adipocytes demonstrated that APP-/- 
adipocytes basally released lower levels of IL-6,GCSF, and sTNFRI compared to 
wild type adipocytes indicating that their phenotype was different (Figure 22D). 
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either APP or CD36 were performed from cultured wild type adipocytes followed 
by blotting with both antibodies. Data are expressed as mean +/- SD (b) (n = 10) 
























from wild type and APP-/- mice, cultured and used for stimulations with our 
without 1g/mL of APP agonist antibody, 22C11, or isotype negative control 
IgG1. Western blots analysis was performed analyzing a variety of differentiation 
and activation markers and (B) values were quantified by normalizing by their 
respective actin loading controls. (C) Representative images from wild type and 
APP-/- adipocytes are shown. (D) Media was collected from stimulated cells for 
cytokine array analysis Data are expressed as mean +/- SD (b) (n = 6) *P<0.05, 
**P<0.01. (D) (n = 4) *P<0.05, **P<0.01, ***P<0.001 vs. Wild type; #P<0.05, 
##P<0.01, ###P<0.001 vs. Wild type IgG1; 
+P<0.05, ++P<0.01, +++P<0.001 vs. Wild 
type 22C11. 
 
Although a receptor-type function of adipocyte APP was not a likely an 
explanation for genotype differences at the cellular or tissue level, it was 
reasonable to expect that the myriad altered cytokine secretions from APP-/- 
macrophages, either basally or in response to stimuli, could be directly 
responsible for the altered adipocyte phenotype. However, another more 
tantalizing possibility was that loss of adipocyte stimulation with an APP 
metabolite such as Aβ, regardless of the cellular source of the peptide, could be 
the source of the adipocyte phenotype differences. In order to test this 
hypothesis, subcutaneous adipocytes were again grown and stimulated with 
Aβ1-40 to simulate release from tissue macrophages or any other relevant cell. 
Adipocytes were stimulated with or without 100nM Aβ to again quantify their 
secretion of IL-6, TNFα, IL-10, IL-4, IL-1β, MCP-1, and adiponectin (Figure 23). 
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As expected, Aβ stimulation did affect wild type cells by specifically increasing 
cytokine secretion of only IL-10. Interestingly, Aβ also stimulated APP-/- 
adipocytes to increase IL-10 secretion along with TNFα, IL-1β, and IL-4. These 
data verified not only that adipocytes respond to Aβ stimulation but also that 
APP-/- adipocytes have an altered secretory response to Aβ. This suggests, 
again, some fundamental activation or differentiation phenotype difference in 
adipocytes from APP-/- mice that could involve altered stimuli from the 
extracellular milieu, including cytokines and Aβ. 
As a negative control to validate whether or not the plethora of changes 
observed in adipose tissue, adipocytes, and macrophages were unique to these 
cells or could expand to any cell type that expressed APP, fibroblasts from wild 
type and APP-/- mice were examined. Specifically, adipose tissue fibroblasts were 
compared. Western blot analysis of the fibroblasts demonstrated that, unlike 
macrophage and adipocytes, fibroblasts exhibited no difference in any of the 
protein levels measured (Figure 24). This supports the notion that changes in 
macrophage and, subsequently, adipocyte behavior resulting from loss of APP is 
the cause of the tissue and animal phenotype differences exhibited by APP-/- 
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Protein quantitation, immunostaining, prostaglandin analysis, and fatty acid 
uptake quantitation in the neurons of APP-/- and wild type mice 
 
Based upon the differences observed in adipose tissue, particularly with 
regard to altered basal and stimulated macrophage phenotype, we assumed that 
similar alterations of brain microglia would occur in control and high fat diet fed   
APP-/- mice.  As we and others have reported (Blume 1989, Forloni 1992, Hung 
1992, Ohyagi 1993, Smith 1993, Sola 1993, Willoughby 1992), neuronal APP 
and reactive microglia immunoreactivity did appear to have slight increases in the 
temporal cortex region of high fat diet fed wild type mice (Figure 25A & 25B). 
Similar to adipose tissue, APP-/- brains exhibited reduced microglial 
immunoreactivity on a control diet but noticeably increased staining in high fat 
diet fed mouse brains (Figure 25B). However, unlike adipose tissue in which 
macrophage demonstrated robust APP immunoreactivity, IBA-1 positive 
microglia had no demonstrable co-localization with APP staining (Figure 25C). 
Several markers of inflammation, gliosis, fatty acid metabolism, and synaptic 
compartments were then compared via Western blot across diet and genotype 
(Figure 25D). Contrary to expectation, high fat diet feeding did not significantly 
increase APP protein levels in wild type mice as we have described in the 
hippocampus (Puig and Combs, 2012) (Figure 26). However, high fat diet fed 
brains had significantly increased levels of phosphorylated tau, CFABP, and 
APOE in wild type but not APP-/- cortex (Figure 26). APP-/- mice on high fat diet 
had reduced CD36, TLR2, TLR4, LRP, CD68, IBA-1, Cox-2, GFAP, CFABP, and 
APOE levels compared to wild type mice on high fat diet. Although there were 
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AKT, glut-4, CFABP, APOE, βIII tubulin (neuronal loading control), or actin 
(general loading control) antibodies.  Arrowheads indicate bands of interest when 
nonspecific bands are present. Antibody binding was visualized by 
chemiluminescence. Blots from all animals in each diet are shown. Brain tissue 
was collected, immersion fixed, serially sectioned, and immunostained using anti-
IBA-1 antibody (microglial marker) or anti-APP antibody (Y188) and binding 
visualized using VIP or DAB as the chromogen. For double-labeling, CD68 
stained tissue sections were stripped using 0.2N HCl and subsequently 
immunostained using anti-APP (Y188) antibody and binding visualized using 
Vector blue as the chromogen. Arrow indicates the location of immunoreactivity 
shown as an enlarged inset to the left of the panel. A representative image from 
5-6 animals per condition is shown. 
 
Also analagous to adipose tissue, several basal differences existed 
between wild type and APP-/- brains fed control diets. APP-/- mice on control diet 
had significantly lower protein levels of the inflammatory markers TLR2 and 
TLR4, the endocytic receptor (LRP), microglial markers CD68 and IBA-1, glucose 
transport receptor (glut4), and CFABP compared to wild type mice on control 
diet. Interestingly, APP-/- mice on control diet demonstrated increased immune 
defense and proinflammatory marker (iNOS), pre-synaptic marker 
(synaptophysin), post synaptic marker (PSD95), and phospho-tau compared to 
wild type mice on control diet. This data again demonstrates a fundamental role 
for APP in regulating both immune and lipid-metabolism associated events. To 
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correlate the change in Cox-2 protein levels with decreased enzyme activity, 
brain levels of PGE2, PGD2, 6-ketoPGF1α, PGF2α and thromboxane B2 were 
quantitated from animals in each diet group (Figure 29B). Both basally and with 
diet, APP-/- mice had significantly less PGE2, PGD2, thromboxane B2 and 6-
ketoPGF1α compared to their diet matched wild type mice. Interestingly wild type 
mice on high fat diet have elevated thromboxane B2 and 6-ketoPGF1α.  Since 
there was a decrease in fatty acid markers as well as prostaglandin levels in 
APP-/- mice we checked to see if this corresponded to changes in fatty acid 
uptake. To assess this, palmitic acid uptake was quantified from cultured cortical 
neurons from wild type and APP-/- brains. Consistent with the blots and 
prostaglandin analysis, APP-/- neurons demonstrated attenuated 16:0 uptake 
ability at each time point examined (Figure 26C). These data directly supported 
the notion that APP regulates fatty acid uptake, at least in a cell type that 
abundantly expresses the protein, neurons. Since a major neuronal fatty acid 
uptake protein, CD36 (Le Foll et al., 2009, Martin et al., 2011, Le Foll et al., 
2013), were decreased in brains of APP-/- mice, it was possible that APP was 
directly involved in regulating fatty acid uptake. To determine whether APP is part 
of a multi-protein complex with CD36, co-immunoprecipitation pull-down 
experiments from cultured neurons were performed. These demonstrated that 
APP and CD36 were part of a multi-protein complex (Figure 26D) supporting the 
possibility that loss of APP alters the fatty acid uptake ability of CD36. Moreover, 
in contrast to adipocytes which express much lower levels of APP, APP appears 
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and analyzed on a quadrupole mass spectrometer to measure levels of PGE2, 
PGD2, 6-ketoPGF1α, PGF2α, and thromboxane B2. (C) At 14 days in vitro, wild 
type and APP-/- neurons were incubated with radiolabeled palmitic fatty acid to 
quantify time dependent uptake. (D) To determine an association between APP 
and CD36, immunoprecipitations of either APP or CD36 were performed from 
cultured wild type neurons followed by blotting with the both antibodies (D). Data 
are expressed as mean +/- SD (n = 5 or 6) *P<0.05, **P<0.01, ***P<0.001.  
 
Since there were significant differences in microglial and inflammatory 
markers in the brains of APP-/- mice versus wild types it was likely that, similar to 
macrophage, microglia would have altered secretory profiles across genotypes. 
To begin addressing this possibility of an altered immune milieu, a cytokine array 
analysis of the temporal cortex lysate was performed. This revealed a significant 
increase in eotaxin-2, fractalkine, IL-2, IL-13, IL-17, I-TAC, KC, MIP-1γ, 
RANTES, and TCA-3 in APP-/- mouse brains supporting the idea once again that 
APP has a fundamental role in regulating both immune and lipid metabolism 
parameters (Figure 27). The fact that many cell types in the brain express APP 
complicated the interpretation of which cells were responsible for the protein 
differences observed by Western blot and cytokine array. However, based upon 
the immunostaining, the most dramatic increase in APP immunoreactivity was in 
neurons. Therefore, primary cortical neurons from  wild type and APP-/- mouse 
brains were grown to determine protein differences existed in vitro similar to 
observed from temporal cortex lysates. Surprisingly, wild type and APP-/- neurons 
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did not differ for any of the same protein markers assessed from the tissue 
samples (Figure 28A & 28B). Since APP function can be stimulated in 
macrophage and microglia it was next determined whether stimulation of APP as 
a cell surface receptor could initiate changes in any of the protein markers. 
Neurons were stimulated with or without the APP agonist antibody, 22C11 to 
examine any subsequent changes in protein expression. However, unlike 
immune cells, antibody-mediated multimerization of APP did not result in any 
change in protein levels (Figure 28C & 28D). This suggested that the complex, 
multi-cell environment of the brain that resulted in robust changes in several 
markers was not replicated in the simplified single cell analysis of cultured 
neurons in spite of the fact that attenuated APP expression altered fatty acid 
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embryonic day 16 wild type and APP-/- mouse brains and cultured serum free for 
14 days in vitro before use. (A) Western blot analysis of several proteins were 
examined and levels (B) quantified by normalizing against respective actin 
loading controls. Data are expressed as mean +/- SD (B) (n = 8) *P<0.05. 
Alternatively, wild type neuron cultures were stimulated with 1μg/mL isotype 
matched negative control antibody IgG1, agonist antibody1μg/mL 22C11, or 
1.2M BACE (β-secretase inhibitor II). (C) Protein levels were examined via 
Western blot and (D) optical densities quantified by normalizing against actin 
loading controls. Data are expressed as mean +/- SD (D) (n = 15). 
 
APP-/- microglia displayed an altered cytokine secretory profile, increased 
proliferation with decreased migration, and reduced phagocytic ability 
 
Neuron culture analysis from wild type and APP-/- mice did not identify any 
robust changes in several proteins examined either basally or with APP 
stimulation. However, other cell types express APP in the brain and the adipose 
tissue analysis suggested that macrophage, even when isolated in vitro, have 
dramatically altered phenotypes compared to wild type cells. To determine 
whether brain microglia also have an altered phenotype in APP-/- mice perhaps 
contributing to the many changes observed in the brain, primary microglia 
cultures were grown from both genotypes. Microglia were stimulated with or 
without common stimulatory ligands, 25ng/mL LPS or 10µM Aβ 1-40 in order to 
quantify the cytokine secretory profliles (Figure 29).  Simulating wild type cells 
with LPS increased secretion of Eotaxin, Eotaxin-2, Fas Ligand, Fractalkine, 
GCSF, IL-3, IL-6, IL-9, IL-10, IL-12p40p70, IL12p70, IL-13, IL-17, I-TAC, KC, 
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MIG, MIP1α, RANTES, SDF-1, TECK, TNFα, and sTNFR1 (Figure 32). 
Stimulating wild type cells with Aβ 1-40 increased secretion of Eotaxin, Fas 
Ligand, Fractalkine, GCSF, GM-CSF, IL-1β, IL-2, IL-3, IL-6, IL-9, IL-10, IL-
12p40p70, IL12p70, IL-13, IL-17, I-TAC, KC, Leptin, MCP-1, MIG, MIP1α, 
RANTES, SDF-1, TECK, TIMP-2, TNFα, and sTNFR1 (Figure 29). Stimulating 
APP-/- cells with LPS increased secretion of only IL-1α and IL-4 (Figure 29). On 
the other hand, stimulating APP-/- cells with Aβ 1-40 increased secretion of BLC, 
Fas Ligand, GM-CSF, INFγ, IL-1α, IL-1β IL-3, IL-4, IL-6, IL-10, IL-12p40p70, Il-
13, IL-17, I-TAC, KC, Leptin, LIX, Lymphotactin, MCP-1, MCSF, MIG, MIP-1α, 
RANTES, TECK, TIMP-1, TIMP-2, TNFα, and sTNFR1(Figure 29). Unstimulated 
APP-/- microglia demonstrated increased GCSF secretion compared to 
unstimulated wild type microglia. In addition, LPS stimulated APP-/- microglia had 
decreased secretion of IL-3, IL-6, IL-10, IL-12p40p70, IL-13, IL-17, RANTES, 
TNFα, and sTNFR1 compared to LPS stimulated wild type microglia (Figure 29). 
On the other hand, Aβ 1-40 stimulated APP-/- microglia showed no difference in 
cytokine secretion compared to Aβ 1-40 stimulated wild type microglia. These 
data supported prior macrophage findings in that only this lineage of cells 
appeared to retain a robust difference in phenotype in vitro. Moreover, these 
secretory data suggest that in addition to observations from macrophage that 
APP appears to regulate each tissue specific macrophage uniquely, APP also 
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strain: Aβ vs Control xP<0.05, xxP<0.01, xxxP<0.001; LPS vs Control +P<0.05, 
++P<0.01, +++P<0.001; Aβ vs LPS #P<0.05. Comparison between strains within 
condition: *P<0.05. **P<0.01, ***P<0.001. 
  
 As a way to further examine changes in microglial phenotype across 
genotypes we quantified their ability to proliferate, migrate through a collagen 
matrix as well as their ability to phagocytize Aβ as a typical ligand in the brain 
(Figure 33). APP-/- microglia had increased proliferation in a 24 hour period 
compared to wild type cells possibly explaining why there was increased 
microglial immunoreactivity in the high fat diet fed brains of the APP-/- compared 
to the APP-/- control diet fed mice but similar to the wild type mice (Figure 28). 
However as expected, APP-/- microglia were not able to migrate as well as wild 
type microglia nor were they able to phagocytize amyloid beta (Figure 33). These 
data support the basally lower levels of microglial immunoreactivity in APP-/- 
brains suggesting that impaired brain infiltration occurs in these mice. 
Collectively, the microglial data indicates that APP plays a role in regulating 
many aspects of the fundamental phenotype of these cells including their 
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AMYLOID PRECURSOR PROTEIN EXPRESSION MODULATES INTESTINE 
IMMUNE PHENOTYPE 
 
 Based upon prior work demonstrating that APP regulates the activation 
phenotype of monocytic lineage cells and since APP expression appeared to co-
localize with macrophage in adipose tissue, we hypothesized that APP can 
regulate macrophage activation phenotype in tissues other than brain. In order to 
compare an environment in which neurons and macrophages are expected to 
abundantly express APP and a range of activating stimuli are continually being 
presented, we chose in this study to compare small intestine of wild type C57BL6 
and APP-/- mice. Based on our previously demonstrated role for APP in 
regulating monocytic lineage cell function, a lack of this protein in the dynamically 
activated immune environment of the intestine should result in significant 
alteration of immune parameters and perhaps neuronal and gut function in 
animals that lack the protein.  
 
Immunoreactivity differences between the ileum of APP-/- and C57BL6 control 
mice 
 
In order to determine histological differences between APP-/- and wild type 



















































































































right of each panel.  Representative images from 5 animals per condition are 
shown. 
 
In order to characterize APP immunoreactivity in the intestine, wild type 
C57BL6 and APP-/- mice ileum of the small intestine was immunostained. Wild 
type mice demonstrated robust APP immunoreactivity within enterocytes and 
neurons and diffuse immunoreactivity within the smooth muscle of the muscularis 
externa (Figure 32). The tissue was then immunostained with a common 
intestine regulatory protein, cyclooxygenase-2 (Cox-2) as well as the tight 
junction protein, occludin, to gain an impression of intestinal phenotype. Both 
Cox-2 and occludin immunoreactivity again appeared primarily localized to the 
enterocyte layer with some areas of robust immunoreactivity for Cox-2 in the wild 
type intestines compared to APP-/- mice (Figure 32). This supported the idea that 
APP expression regulates some aspects of intestinal immune cell behavior as 
well as that of enterocytes.  
Based upon the fact that a portion of the APP immunoreactivity was 
clearly localized to neurons in wild type mice, the tissue was also stained with an 
anti-microtubule associated protein 2 (MAP2) antibody to visualize the integrity of 
the enteric plexi in the intestines. As expected, wild type mouse sections 
demonstrated robust immunoreactivity throughout the submucosa and lamina 
propria while the APP-/- sections had visibly less immunoreactivity (Figure 32). 
This suggests that lack of APP expression also modulates neuronal integrity and 
likely enteric function in the small intestine.  Since there was no obvious 
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immunoreactivity for APP observed within macrophages or other cell types 
throughout the intestinal layers (Figure 32) we then examined other cell types in 
the ileum of the small intestine.   Wild type intestines demonstrated robust anti-
CD68 immunoreactivity to identify macrophages while APP-/- mice presented with 
a markedly decreased staining (Figure 33) suggesting either decreased 
activation or decreased numbers in the intestine. Because the phenotype of 
astrocyte-like enteric glia can contribute to maintenance of gut barrier integrity 
and inflammatory state (Savidge et al., 2007, Cirillo et al., 2011) we next 
assessed activation state of these cells.  
Based upon the fact that a population of enteric glia are astrocytic in 
nature (Jessen and Mirsky, 1985) we immunostained the ileum of the small 
intestine with anti-GFAP antibodies (Figure 33).  The GFAP immunoreactivity 
appeared to localize to the external portion of the muscularis externa. Unlike 
neuron and macrophage immunoreactivities there was no visible difference in 
astrocyte-like immunoreactivity between the wild type and APP-/- intestine (Figure 
33).  To assess if APP expression resulted in tyrosine kinase activation in the 
ileum of the small intestine as another potential marker of immune cell 
macrophage activation, the ileum was stained with anti-pTyr antibodies. 
However, there was no obvious difference in pTyr immunoreactivity between wild 
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indicate the location of immunoreactivity shown as an enlarged inset to the right 
of each panel.  Representative images from 5 animals per condition are shown.   
 
Quantitation of protein differences in the ileum of C57BL6 wild type and APP-/- 
mice 
 
Based upon the qualitative changes in immunoreactivity patterns 
observed, it was necessary to quantify whether there were indeed protein level 
changes in wild type versus APP-/- intestine. Ileum samples were analyzed to 
determine whether the changes observed by immunohistochemistry were 
significant. As expected, Western blot analysis demonstrated that Cox-2 and 
CD68 levels were significantly decreased in the APP-/- mice compared to wild 
type controls with no difference in occludin, GFAP, and pTyr (Figure 34) 
consistent with the immunostaining observed (Figure 10). To assess whether 
other immune cell types present in the intestine besides macrophages were 
altered in APP-/- mice, Western blots for markers of T-cells (CD3), B-cells 
(CD40), as well as dendritic cells (CD11c) were quantified.  Although there was 
no change in CD3 levels there was a significant decrease in CD40 and CD11c 
protein levels in the APP-/- compared to the wild type mice (Figure 12). As a 
measure of neuronal integrity, presynaptic and postsynaptic markers were also 
examined by Western blot. Interestingly, the total amount of neuronal βIII-tubulin 
protein levels was decreased in APP-/- as compared to wild type mice, with no 
difference in protein levels of the presynaptic (synaptophysin) or postsynaptic 
(PSD95) protein markers (Figure 34). This decrease in βIII-tubulin levels was 
consistent with the observed decrease in dendritic marker, MAP2, 
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immunoreactivity in APP-/- mice (Figure 32). A change in macrophage, B cell, and 
dendritic cell protein levels could correlate with altered expression of 
immunomodulatory receptors in the intestine. Therefore, critical pattern 
recognition receptor, TLR2 and TLR4, protein levels were examined as well. 
However there was no change in expression of either TLR between wild type and 
APP-/- ileum of the small intestine (Figure 34).  Finally, protein levels of necessary 
fatty acid transport proteins was assessed as an additional means of examining 
changes in intestinal barrier integrity. CD36 and FATP4 protein levels were 
analyzed, with again, no difference in expression between the wild type and   
APP-/- ileum of the small intestine (Figure 34) suggesting again that epithelial 
function may be preserved in the APP-/- intestines. 
 
In vitro migration, proliferation, and differentiation comparison of macrophages 
from APP-/- and C57BL6 wild type mice 
 
Since Western blot analysis had validated that protein differences existed 
in neuronal proteins and enterocyte proteins in APP-/- compared to wild type 
mice, we next sought to further examine the changes in CD68 positive 
macrophage immunoreactivity observed in the APP-/- ileums. As intestinal 
macrophages have previously been shown to have very different responses to 
LPS (Grimm et al., 1995, Rogler et al., 1998), both peritoneal and intestinal 
macrophages have been included in our analysis as both contribute to the 
immunomodulatory behavior of the ileum of the intestine.  One possibility for the 
decrease in CD68 immunoreactivity might simply be that APP-/- cells were less 




















































































ileum proteins were normalized against their respective actin (Cox-2, CD68, 
CD3, CD40, CD11c, GFAP, TLR2, TLR4, CD36, FATP4, pTyr and occludin) or 
βIII tubulin (synaptophysin and PSD95) loading controls and averaged (+/- SD) 
from 10 animals per each condition *P<0.05, **P<0.01.  
 
As a means of testing this idea, we isolated non-elicited peritoneal 
macrophages and intestinal macrophages from wild type and APP-/- mice at 2 
months of age and compared the ability of these cells to migrate through a 
transwell culture insert in vitro. As expected, APP-/- peritoneal macrophages 
demonstrated a significantly decreased ability to migrate through the insert into 
the LPS containing media below compared to wild type peritoneal cells. 
However, there was no significant difference in the migratory behavior of wild 
type and APP-/- intestinal macrophages (Figure 35A and 35B).  Another 
possibility for decreased CD68 immunoreactivity in the APP-/- ileums could be 
due to an impaired differentiation or proliferation ability of APP-/- cells. As a 
means of assessing proliferative ability of the cells, peritoneal and intestinal 
macrophages from wild type and APP-/- animals were grown in the presence of 
serum for 72 hours. However, there was no significant difference in proliferative 
ability in vitro of either type of macrophage (Figure 35C and 35D). To examine 
differentiative or activation phenotype differences between the two genotypes, 
collected macrophages were stimulated 24 hr in the absence or presence of the 










































































































Based upon prior analysis of abundant peritoneal macrophages in vitro 
secretion, keratinocyte chemokine (KC), and interleukin-6 (IL-6) levels were 
quantified from the media as representative secretory factors from peritoneal and 
intestinal macrophages. Although there were no differences in LPS-stimulated 
levels between genotypes for KC cytokine secretion in the peritoneal 
macrophages, the APP-/- peritoneal macrophages secreted significantly less KC 
compared to wild type cells during basal, unstimulated conditions (Figure 36A).  
LPS-stimulated wild type peritoneal macrophages had increased secretion of IL-6 
compared to LPS-stimulated APP-/- and untreated wild type peritoneal 
macrophages (Figure 36C).  The LPS-stimulated intestinal macrophages had no 
change in secretion of KC or IL-6 compared to basal levels, suggesting that 
intestinal macrophages are unresponsive to LPS (Figure 36B and 36D).  
However, LPS stimulated APP-/- intestinal macrophages had increased secretion 
of KC compared to LPS stimulated wild type intestinal macrophages.  As well as, 
basally APP-/- intestinal macrophages secreted more KC than wild type intestinal 
macrophages (Figure 36B).  
As a follow up to the decreased migratory behavior of the APP-/- peritoneal 
macrophages, Regulated upon Activation, Normal T-cell Expressed, and 
Secreted (RANTES) was measured from peritoneal macrophages stimulated with 
and without LPS (Figure 36E).  As with the secretion of KC, LPS increased 
RANTES secretion with no significant difference between wild type and APP-/- 
peritoneal macrophages (Figure 36E).  To further compare phenotype 
differences particularly in intestinal macrophages, interleukin-1 beta (IL-1β) was 
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next measured. Again as with KC and IL-6, LPS stimulation had no effect on wild 
type intestinal macrophages. However, LPS significantly increased secretion of 
IL-1β from the APP-/- intestinal macrophages as compared to the unstimulated 
APP-/- intestinal macrophages as well as the LPS stimulated wild type intestinal 
macrophages (Figure 36F).  Collectively, these findings suggest that peritoneal 
and intestinal macrophages of APP-/- mice are phenotypically different with 
impaired migratory ability in peritoneal macrophages compared to their intestinal 
counterparts. More importantly, in spite of an apparent decrease in numbers of 
CD68 positive macrophages in the ileum of APP-/- mice, these cells appear, to 
some degree, hyperreactive basally and in response to LPS stimulation when 
compared to wild type intestinal macrophages.  
 
Profile of cytokine levels in ileum of APP-/- and C57BL6 wild type mice 
Based upon the in vitro macrophage secretory differences observed, the 
reduced CD68 ileum macrophage immunoreactivity, and the reduced protein 
levels of CD68, CD40, and CD11c it was reasonable to expect that levels of 
cytokines in the APP-/- versus wild type ileums as a whole would also differ. To 
examine this possibility, ileums were collected from 7 month old animals and 
used to perform antibody-based cytokine arrays profiling 40 different cytokines. 
As expected, the APP-/- ileums demonstrated significantly decreased levels of 12 
different factors, CD30L, Eotaxin, Fas Ligand, Fractalkine, GCSF, IL-10, IL-
12p40p70, IL-3, IL-9, MIG, MIP-1γ, and sTNFRI, compared to wild type mice 



































Non-elicited peritoneal macrophages and intestinal macrophages were isolated 
from C57BL6 wild type and APP-/- mice. Macrophages were stimulated with or 
without 25ng/mL LPS, 24hr in serum-free DMEM/F12. Media was collected to 
quantify basal and stimulated secretion of KC, IL-6, RANTES and IL-1β. The 
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and APP-/- mice were collected, lysed, and used in an antibody cytokine array. 
APP-/- mice demonstrated decreased CD30L, Eotaxin, Fas Ligand, Fractalkine, 
GCSF, IL-10, IL-12p40p70, IL-3, IL-9, MIG, MIP-1γ, and sTNFRI compared to 
wild type mice. A representative array for one animal from each genotype is 
shown. Optical densities of normalized dot intensities from 6 animals in each 
group are displayed as mean (+/-SD). *p<0.05 
 
Differences in intestinal motility and absorption in APP-/- and C57BL6 mice 
A combined change in levels of multiple cytokines, proinflammatory and 
regulatory proteins, numbers of macrophages, and finally neuronal synaptic 
markers all suggest that the function of APP-/- intestines would differ significantly 
compared to wild type control animals. In order to address intestinal function, 
mean stool production and water content were compared between the 
genotypes. Although this was not exclusively an assessment of small intestine 
behavior, APP-/- animals generated significantly more stool per time period with 
increased water content (Figure 38A). This suggested increased motility and 
decreased absorption in the intestine of APP-/- mice, which correlated with 
reduced body mass in these mice (Figure 38B). This suggests that APP-/- may 
have reduced weight gain ability due to increased motility and reduced 
absorption. Moreover, the adverse consequence of decreased absorption in the 
smaller APP-/- mice likely has a significant effect on overall physiology. As an 
additional means of assessing absorption, plasma levels of LPS were quantified 
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uptake of LPS were quantified from C57BL6 wild type and APP-/- mice. (A) To 
assess stool production and water absorption, wet and dry stool weights and the 
differences (water content) were collected over 1hr.  Data from 13 animals in 
each group are displayed as mean (+/-SD). (B) To assess animal weight 
difference between strains, mice were weighed prior to collection. (C) To quantify 
uptake/transport of intestinal LPS into blood, whole blood was collected, plasma 
was separated and the LAL Endotoxin assay was performed according to 




















OVEREXPRESSION OF MUTANT AMYLOID PRECURSOR PROTEIN AND 
PRESENILLIN 1 MODULATES INTESTINE IMMUNE PHENOTYPE 
 
 Based upon the work in our previous chapter demonstrating that a lack of 
APP resulted in profound regulatory effects on protein expression in a range of 
small intestine cells including neurons, CD68 positive macrophages, and 
enterocyte epithelial cells which influenced the expression of multiple cytokine 
levels and intestinal motility changes, we hypothesized that overexpression of 
APP would also alter the intestinal phenotype. Therefore in this study we 
compare the small intestine of wild type C57BL6 and APP/PS1 mice to assess 
immune parameters and neuronal and gut function in response to increased APP 
and its metabolite Aβ. 
 
Histological differences were observed between the ileums of APP/PS1 and wild 
type mice 
 
Because our prior work had demonstrated dramatic plaque deposition and 
microgliosis in the brains of this particular strain of AD mouse model at 12-13 
months of age, we elected to use 13 month old animals to examine any changes 
in intestines (Dhawan and Combs, 2012). As a representative section of the GI 
tract, we again focused our examination on the ileums (Puig and Combs, 2012). 
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Significant differences in neuronal and inflammatory proteins were observed from 
ileum of APP/PS1 mice 
 
The H&E staining prompted us to examine specific protein markers of 
immune cell change via Western blot to quantify any differences in wild type 
versus APP/PS1 ileums. Not only APP but also BACE levels were significantly 
increased in the APP/PS1 mice (Figure 40A and 40B). To delineate which 
immune cells were in fact increased as shown by the H&E staining, we quantified 
markers of macrophage (CD68), dendritic cells (CD11c), B-cells (CD40), and T-
cells (CD3).  Although there were no differences between strains in CD11c and 
CD40 levels, APP/PS1 mice demonstrated a significant increase in CD68 and 
CD3 protein levels compared to the wild type mice (Figure 40A and 40B). The 
increase in CD68 is similar to the increase we have prior observed in the brains 
of 12 month old APP/PS1 mice compared to wild type controls (Dhawan and 
Combs, 2012). To further characterize any inflammatory response in APP/PS1 
mice, we quantified an increase in their Cox-2 protein levels compared to wild 
type mice. In order to examine whether any changes in intestinal barrier integrity 
or epithelial phenotype existed, we quantified CD36 (integral membrane protein) 
and occludin (tight junctional marker) levels. APP/PS1 mice had elevated CD36 
but no occludin levels compared to the controls (Figure 40A and 40B). As a 
measure of neuronal integrity, presynaptic and postsynaptic markers were also 
examined by Western blot. Interestingly, APP/PS1 mice demonstrated increased 
protein levels of presynaptic (synaptophysin) and postsynaptic (PSD95) protein 
markers (Figure 40A and 40B). Because our prior work has demonstrated that 
APP and Aβ stimulation of immune cells is associated with tyrosine kinase-
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mediated signaling (Sondag et al., 2009, Dhawan et al., 2012) we also 
determined whether any changes in overall protein phosphor-tyrosine (pTyr) or 
active phospho-Src (pSrc) levels existed in APP/PS1 mice compared to controls.  
However, APP/PS1 mice did not significantly differ in pTyr or pSrc levels 
compared to wild type control mice (Figure 40A and 40B). 
 
No significant increase in quantitated Aβ levels were detected in the stool or 
intestinal lysate of APP/PS1 compared to wild type mice 
 
In order to quantify Aβ levels in the ileums, intestinal lysates and stool 
washings were collected and used in Aβ 1-40 and Aβ 1-42 ELISAs. However, 
contrary to our expectations and the increased APP and BACE levels in the 
Western blot analysis (Figure 40A and 40B), no quantifiable increase in Aβ 1-40 
or Aβ 1-42 was observed in the intestinal lysate or the stool washings (Figure 
40C).  
 
Immunohistological differences were observed between the ileums of APP/PS1 
and wild type control mice 
 
To provide qualitative cellular localization in support of the quantitative 
Western analysis, immunohistochemistry was performed. APP/PS1 and wild type 
mice demonstrated APP immunoreactivity within enterocytes and neurons and 
diffuse immunoreactivity within the smooth muscle of the muscularis externa with 
increased intensity in the APP/PS1 mice (Figure 41). Both strains demonstrated 
fibrillar Aβ (OC) immunoreactivity in the enterocytes, oligomeric Aβ (A11) and 
4G8 immunoreactivity in the neurons and diffuse immunoreactivity within the 
smooth muscle of the muscularis externa (Figure 41). There appeared to be a 
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slight increase in fibrillar (OC) and 4G8 Aβ reactivity in the APP/PS1 compared to 
the wild type with no difference in oligomeric Aβ (A11) staining between the two 
strains (Figure 41). 
To assess changes in particular cell types throughout the intestinal layers 
we further examined the ileum of the small intestine with a cell-selective 
antibodies marker.  APP/PS1 intestines demonstrated robust increased anti-
CD68 immunoreactivity to identify macrophages compared to the wild type 
ileums (Figure 42) suggesting either increased activation or increased numbers 
in the intestine, consistent with the increased CD68 levels observed via Western 
blot and the increased immune cell detection in the H&E stains. To further 
assess intestinal integrity, the tissue was then immunostained with a common 
intestine regulatory and proinflammatory protein, cyclooxygenase-2 (Cox-2), a 
tight junction protein, occludin, as well as, the integral membrane protein, CD36, 
to gain an impression of intestinal phenotype. Cox-2, CD36 and occludin 
immunoreactivity again appeared primarily localized to the enterocyte layer with 
some areas of robust immunoreactivity for Cox-2 and CD36 in the APP/PS1 
intestines compared to the wild type mice (Figure 42). This collective staining 
supported the idea that mutant APP/PS1 expression regulates some aspects of 
intestinal immune cell behavior as well as that of enterocytes, suggesting that 



































intestine was collected from APP/PS1 and C57BL6 wild type mice.  The tissue 
was lysed, resolved by 10-15% SDS-PAGE and Western blotted using anti-APP, 
BACE, CD68, CD11c, CD40, CD3, Cox-2, CD36, occludin, synaptophysin, 
PSD95, MAP2, pTyr, pSrc, cSrc (loading control), or actin (loading control) 
antibodies.  Antibody binding was visualized by chemiluminescence. Blots from 
all animals are shown.  Optical densities of the Western blotted ileum proteins 
were normalized against actin loading control and averaged (+/- SD) from 5 
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immunostained.  Tissue sections were immunostained using anti-CD68, Cox-2, 
CD36 and occludin antibodies and antibody binding was visualized using Vector 
VIP as the chromagen. Arrows indicate the location of immunoreactivity shown 
as an enlarged inset to the right of each panel.  Representative images from 5 
animals per condition are shown.   
 
Since a portion of the APP immunoreactivity was clearly localized to 
neurons in APP/PS1 and wild type mice and pre and post-synaptic markers were 
increased in the mutant animals by Western blot, the tissue was stained with an 
anti-synaptophysin and anti-microtubule associated protein 2 (MAP2) antibodies 
to better visualize the integrity of the enteric plexi in the intestines. However, wild 
type and APP/PS1 mouse sections demonstrated equally robust 
immunoreactivity throughout the submucosa and lamina propria (Figure 43). To 
determine whether cell-selective changes in tyrosine kinase-mediated signaling 
would localize to immune cells, the ileum was stained with anti-pTyr and pSrc 
antibodies. However, consistent with the Western blot analysis, there were no 
obvious differences in immunoreactivity intensity and staining appeared to 





































































shown as an enlarged inset to the right of each panel.  Representative images 
from 5 animals per condition are shown. 
 
No differences in intestinal motility but increased cytokine and IgA levels were 
observed in APP/PS1 versus wild type mice 
 
Based upon the increased Cox-2 and CD68 and CD3 levels as well as 
increased CD68 immunoreactive macrophage in the APP/PS1 ileums, it was 
reasonable to expect that levels of cytokines in the APP/PS1 versus wild type 
ileums would also differ. To examine this possibility, ileums were collected from 
13 month old animals and used to perform antibody-based cytokine arrays 
profiling 40 different cytokines. As expected, the APP/PS1 ileums demonstrated 
significantly increased levels of 6 different factors, IL-12p70, LIX, MCP-1, MCSF, 
SDF-1, and TIMP-1 compared to wild type mice (Figure 44). These findings were 
consistent with the immunohistochemistry and protein expression changes 
suggesting proinflammatory and immune changes and further supported the 
notion that mutant APP/PS1 expression regulates immune cell phenotype in the 
intestine. 
 A combined change in levels of multiple cytokines, proinflammatory and 
regulatory proteins, and numbers of macrophages, suggested that the function of 
APP/PS1 intestines may differ significantly compared to wild type control animals. 
In order to address intestinal function, mean stool production and water content 
were compared between the genotypes. Although this was not exclusively an 
assessment of small intestine behavior, APP/PS1 animals did not generate any 
difference in stool or water content (Figure 45A).  
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Even though an overall difference in stool or water content was not seen 
the APP/PS1 mice compared to controls, the changes observed thus far were 
actually more indicative of immune dysfunction. Therefore, luminal intestinal 
content was compared between genotypes using a commercially available IgA 
ELISA.  There was increased IgA secretion in the APP/PS1 intestinal lumen 
compared to the wild type mice again supporting the notion that immune 




































































































absorption and motility, water and stool production were quantified from C57BL6 
wild type and APP/PS1 mice. To assess stool production and water absorption, 
wet and dry stool weights and the differences (water content) were collected over 
1hr.  Data from 5 animals in each group are displayed as mean (+/-SD). Small 
intestine was washed with 7mL of HBSS to remove intestinal contents. Samples 
were diluted 1:5000 and 300uL of sample was added to the Elisa plate. Data 
from 7 animals in each condition are displayed as mean (+/-SD). **P<0.01 
 
Human intestinal epithelial cells secrete, take up, and respond to Aβ 
The 4G8 immunoreactivity observed in the APP/PS1 intestine suggested 
that cells were making and secreting Aβ perhaps as the source of macrophage 
activation and immune changes. Neuronal secretion of Aβ has been well 
described so we focused instead on the possibility that the enterocyte 
immunoreactivity for APP indicated that these cells could also be secreting Aβ 
peptide. To examine this possibility, we cultured the human enterocyte cell line, 
Caco-2, and stimulated them with and without a luminal relevant ligand, the 
bacterial endotoxin, lipopolysaccharide (LPS).  Caco-2 cells secreted both        
Aβ 1-40 and Aβ 1-42, with higher quantifiable amounts of Aβ 1-40 compared to 
Aβ 1-42 upon stimulation with LPS (Figure 46A).  Since Aβ 1-40 was the more 
abundantly secreted form of the peptide, we examined the possibility that 
enterocytes could be stimulated in an autocrine fashion in response to the 
peptide. To begin examining this, Caco-2 cells were incubated with fluorescently 
labeled Aβ 1-40 again in the absence or presence of the luminal ligand, LPS. 
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Caco-2 cells could, in fact, take up Aβ peptide although this was not affected by 
the presence of LPS (Figure 46B).  
To determine whether the Aβ interaction altered Caco-2 phenotype in a 
fashion consistent with the immunohistochemistry and Western findings from 
mouse ileums, protein changes were examined in cells stimulated with increasing 
concentrations (100nM, 1µM, 5µM) of Aβ 1-40 or LPS. To confirm that our Aβ 
and LPS treatments were not causing cell death, cell viability was quantified via 
an MTT assay (Figure 46C). However, Western blot analysis of cell lysates 
indicated that neither Aβ nor LPS altered protein levels of APP, CD36, occluding 
or pSrc (Figure 46D and 46E). On the other hand, ELISA analysis from media 
collected from the stimulated cells showed that 1µM Aβ 1-40 increased IL-6 
cytokine secretion by the Caco-2 cells (Figure 8F). These results indicate that 
enterocytes also have the potential to not only make Aβ but autocrine respond to 
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measured with a fluorescent plate reader (480 nm excitation and 520 nm 
emission). Caco-2 cells were treated overnight and then assessed via MTT 
assay to assess viability. Data are from 3 experiments in a replicate of 8 
displayed as mean (+/-SD). *P<0.05. To assess protein expression Caco-2 cells 
were stimulated and then lysed for Western blotting. To demonstrate treatment 
effects on cytokine secretion cells were treated overnight and media was 
analyzed via IL-8, MCP-1, MDC, IL-6 and TNFα Elisas. Data are from 6 samples 






















 This work provides a novel data set demonstrating that APP expression 
has a dramatic regulatory effect on a variety of cell types beyond neurons. Our 
paradigm focused on high fat diet dependent changes in cells in the brains and 
adipose tissue primarily with a focus on macrophage and microglia. Consistent 
with our hypothesis, APP clearly regulates microglial and macrophage phenotype 
in a tissue specific fashion working directly as a receptor as well as providing a 
source of stimuli to these cells in the form of A peptides. The myriad effects on 
these cells ranged from not only alteration of their secretory profile but also 
differences in their migratory ability, proliferation rate, and phagocytic ability. This 
is entirely consistent with our prior work and supports the idea that APP is a 
proinflammatory receptor that is involved in modulating tissue macrophage 
phenotypes in any number of conditions or diseases. Future work will determine 
in a cell-specific fashion precisely which conditions require a role for APP or Aβ 
effects on macrophage. This could lead to a role to a currently underappreciated 
role for APP in numerous immune dysfunction conditions providing a potential 
new target for intervention. 
 An additional and unexpected outcome from the study was the finding that 
numerous changes in lipid metabolism associated proteins were altered in not 
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only isolated cells but also tissue from APP-/- animals both on control and high fat 
diets. This was supported by the fact that APP-/- mice, unlike their wild type 
counterparts, were unable to increase APP levels in adipose tissue and brain and 
had attenuated adipocyte hypertrophy and weight gain when fed high fat diets. 
This data set not only demonstrated that high fat diet induced early Alzheimer’s 
disease-like changes in the brain but also adipose tissue. This suggests that 
adipose tissue changes might parallel and serve as a surrogate tissue for 
monitoring brain changes with disease. Perhaps even more importantly, these 
data demonstrated that APP expression is required for high fat diet dependent 
weight gain and adipose tissue hypertrophy. This is the first demonstration, to our 
knowledge, of data clearly linking APP to high fat diet dependent obesity, a major 
risk factor for Alzheimer’s disease. Although the precise mechanism linking loss 
of APP to the lipid –associated protein and adipose tissue changes is not entirely 
resolved, it is feasible that the altered inflammatory milieu produced by the APP 
deficient macrophage in each tissue, brain and adipose, contributes to the 
changes observed. Alternatively, it may be that APP has a direct and currently 
unknown role in regulating cellular fatty acid uptake. Although this was not 
supported by fatty acid uptake and oil red O analysis from APP-/- adipocytes, 
neurons grown from APP-/- mice clearly had attenuated fatty acid uptake. This 
was supported by the fact that neurons and not adipocytes had APP associated 
with the fatty acid uptake protein, CD36. One explanation is simply that cells 
which express high levels of APP, like neurons, utilize APP as a fatty acid uptake 
regulatory protein while other cells, like adipocytes, have their altered phenotype 
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due to loss of stimuli from cytokines or A in an APP-/- environment. Again, future 
work will need to determine, apparently in a cell-specific fashion, precisely how, 
and if, APP regulates fatty acid uptake, storage, or turnover. This also suggests 
the exciting possibility that APP or stimulation with its metabolites directly 
regulates lipid metabolism. Again, this supports the abundant data linking midlife 
obesity with increased risk of Alzheimer’s disease. At the very least, the APP 
changes observed may serve as one of the growing list of bio-markers that 
identify obesity-related changes. 
Our results provide a crucial data set of comparison changes in brain 
versus adipose tissue that was lacking from earlier studies which have focused 
on a particular organ. Prior work from human subjects has demonstrated 
increased adipose tissue APP and plasma Aβ levels in obese subjects 
(Balakrishnan et al., 2005, Lee and Pratley, 2007, Lee et al., 2008a, Lee et al., 
2009a, Sommer et al., 2009) although comparable brain data was not reported. 
Similarly, brain but not adipose data from Alzheimer’s disease transgenic rodent 
studies using diet-induced obesity paradigms have indicated that obesity 
correlates with increased levels of brain Aβ (Levin-Allerhand et al., 2002, Ho et 
al., 2004, Kohjima et al., 2010) although not necessarily an increase in full length 
APP as we observed. Our findings are in greater agreement with those of 
Thirumanagalakudi and colleagues who found using wild type C57BL6/J mice 
that a high fat/high cholesterol diet induced increased brain changes in APP, Aβ, 
and diverse proinflammatory proteins (Thirumangalakudi et al., 2008) although a 
related study in C57BL6/J mice reported no change in brain APP or Aβ levels 
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(Moroz et al., 2008). To link these diverse data sets we suggest, that based upon 
our findings, a high fat feeding paradigm producing a diet-induced obesity in 
animals expressing APP under the control of its endogenous promoter is 
sufficient to increase APP expression in both adipose and brain tissue 
simultaneous with similar proinflammatory changes that occur in each tissue. 
It is not clear what the exact stimulus is to increase APP levels in the cell 
types in our paradigm although we speculate that proinflammatory stimuli are 
responsible. It is well established that obesity correlates with a host of increased 
circulating proinflammatory molecules (van Dielen et al., 2001, Poitou et al., 
2006, Antuna-Puente et al., 2008, Fain, 2010) released by both adipocytes and 
adipose macrophage (Fain, 2006, 2010, Fain et al., 2010).  Prior work from the 
3T3-L1 adipocyte cell line has demonstrated that stimulation with TNF-α is 
sufficient to increase APP expression (Sommer et al., 2009). We (Sondag and 
Combs, 2004a, 2006b, 2010a) as well as others (Schmechel et al., 1988, Bauer 
et al., 1991, Haass et al., 1991, Banati et al., 1993, Banati et al., 1994a, Banati et 
al., 1994b, Monning et al., 1994, Banati et al., 1995a, Banati et al., 1995b, 
Gehrmann et al., 1995a, Gehrmann et al., 1995b, Monning et al., 1995) have 
demonstrated that APP expression and plasmalemmal localization in monocytic 
lineage cells, including macrophage and microglia, increases during 
proinflammatory or degenerative conditions. Finally, neurons themselves have a 
well-established ability to increase APP expression during diverse degenerative 
and inflammatory stimulations (Blume and Vitek, 1989, Forloni et al., 1992, Hung 
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et al., 1992, Willoughby et al., 1992, Ohyagi and Tabira, 1993, Smith et al., 1993, 
Sola et al., 1993).  
It is important to point out that the focus of this work was on the particular 
cellular changes in full-length APP rather than assessment of APP processing to 
Aβ. However, we did assess potential Aβ generation and deposition in both brain 
and visceral and subcutaneous adipose tissue via immunostaining. Although the 
mouse Aβ-specific antibody detected no robust changes in either tissue from 
control or high-fat diet fed mice it is possible that Aβ production was increased in 
parallel with the increased APP protein levels observed in high fat diet-fed mice 
but was simply not detectable via immunostaining. We have not ruled out the 
possibility that a longer feeding paradigm and more sensitive detection method 
such as an Aβ ELISA might demonstrate a significant difference in APP 
processing to increased levels of Aβ between diets.  
Indeed, prior work has already demonstrated that high fat/cholesterol 
feeding increases Aβ levels in the murine brain (Thirumangalakudi et al., 2008). 
This indicates, perhaps not surprisingly, that although APP levels were increased 
in brain and adipose tissue, its processing and perhaps function(s) is unique 
based upon cell type expression and requires future study. Regardless of what 
cell type is potentially producing the Aβ in brain and adipose tissue, the peptide 
in either its oligomeric or fibrillar form has been shown in numerous studies to be 
a potent stimulus for activating microglia and monocyte/macrophage cells to 
acquire a reactive phenotype (Meda et al., 1995, Bitting et al., 1996, Lorton et al., 
1996, Combs et al., 1999, Lorton et al., 2000, Lue et al., 2001, Wu et al., 2004, 
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Sondag et al., 2009). Again, although processing of APP to Aβ was not the focus 
of this work, it is intriguing to consider that in addition to proinflammatory stimuli 
potentially driving increased APP expression, increased Aβ production may act in 
a feed-forward fashion to increase proinflammatory secretions in brain and 
adipose tissue by directly stimulating microglia and macrophage/adipocytes, 
respectively. Indeed, our data demonstrated that A was a potent activating 
stimulus to these cells. These data support the idea that limiting inflammatory 
changes during diet induced weight gain may not only attenuate pathologic 
events in peripheral organs but also those in the brain. In fact, the use of non-
steroidal anti-inflammatory drugs during mid-life, in particular, may offer some 
protective benefit against developing AD (Hayden et al., 2007). 
Although our study has focused specifically on changes related to diet 
induced obesity it is difficult not to speculate that the changes observed may be 
directly relevant to the mechanism of Alzheimer’s disease. As already mentioned, 
mid-life obesity is a well-recognized increased risk factor for developing AD 
(Kivipelto et al., 2005, Whitmer, 2007, Beydoun et al., 2008, Profenno and 
Faraone, 2008, Fitzpatrick et al., 2009, Profenno et al., 2010) and several rodent 
studies using transgenic mouse models of AD have demonstrated that diet-
induced obesity paradigms increase Aβ levels in the brain (Levin-Allerhand et al., 
2002, Ho et al., 2004, Kohjima et al., 2010). More importantly, caloric restriction 
of these transgenic models is sufficient to decrease brain Aβ levels and plaque 
load (Wang et al., 2005a). It was particularly interesting that microglia isolated 
from high fat diet fed mice basally secreted elevated levels of TNFα compared to 
156 
 
microglia from control diet fed mice. The ability to isolate these cells acutely from 
adult mouse brains without the confound of prolonged in vitro culturing in serum 
containing conditions allows us to quantify with confidence the basal microglial 
secretory phenotype in the brain during either diet paradigm. The elevated 
proinflammatory state suggested by the glia was supported by elevated levels of 
total prostaglandins in the high-fat diet fed mice. Although we did observe 
dramatic effects of APP stimulation on neuronal phenotype in this study it is 
interesting to speculate that APP-dependent stimulation of neurons may lead 
directly to increased neuronal prostaglandin production as well as generation of 
Aβ that may be direct stimuli for the increased microglial TNFα secretion that 
occurred in high-fat diet fed brains. This APP-dependent mechanism linking 
generation of these proinflammatory mediators with gliosis would certainly be 
reasonable to consider during similar degeneration events in AD. 
Perhaps even more interesting is the possibility that APP dependent 
proinflammatory events contribute to the classic inflammatory changes 
commonly observed in peripheral adipose tissue during diet-induced obesity. For 
instance, based upon the increased APP levels observed in macrophage and 
adipocytes, we examined a role for APP in regulating the phenotype of these 
cells. Although we were unable to determine any phenotype change in adipocyte 
downstream of APP stimulation, they were stimulated by Aβ. In addition, 
macrophage exhibited a significant increase in secretion of three particular 
cytokines out of the 40 analyzed that may be relevant to adipose changes 
observed during high fat diet feeding. APP stimulation increased macrophage 
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secretion of GM-CSF, IFNγ, and IL-13. GM-CSF has a well characterized role in 
regulating infiltration of macrophage into adipose tissue (Kim et al., 2008). An 
APP-dependent increase in GM-CSF secretion would certainly help to explain 
some of the observed increased in reactive macrophage in the high fat diet 
adipose tissue. IFNγ has an increasingly apparent role in regulating not only 
adipocyte cytokine secretion including TNFα but also insulin resistance and 
infiltration of T cells into obese adipose tissue (Rocha et al., 2008, McGillicuddy 
et al., 2009, O'Rourke et al., 2009). Elevated IL-13 expression is a hallmark of 
recently defined alternative M2 phenotype macrophage in obese adipose tissue 
(Shaul et al.). Although APP stimulation did not alter adipocyte phenotype in our 
hands, A stimulation did, and a more extensive assessment would likely identify 
APP and A dependent changes in adipocytes relevant to obesity.  
One interesting possibility is that an APP-APP dependent interaction 
between adipocytes and macrophage is involved in activating both cell types.  
That is, APP on macrophage may interact with APP on adipocytes in a complex 
trans APP-APP interaction as APP can act as a receptor for monocytic lineage 
cells (Sondag and Combs, 2004a). It is known that although adipocytes are quite 
capable of secreting a range of inflammatory molecules (Meijer et al.) that 
macrophage-adipocyte interaction can potentiate inflammatory changes that can 
occur during obesity and metabolic disorder (Nakarai et al.). Determination of 
specific roles for APP in macrophage and adipocyte changes during high fat diet 
feeding might be addressed in future work through the use of cell selective APP 
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knockout mice or cells selective expression of mutant forms of APP such as 
those associated with AD. 
As already suggested, an interesting speculation is that if APP and/or Aβ 
levels increase in adipose tissue during obesity and AD and coordinated 
expression is tightly regulated between brain and fat then it is not unreasonable 
to predict that monitoring APP expression and metabolism in adipose tissue 
could serve as a surrogate for brain with regard to assessing efficacy of particular 
drug interventions or monitoring disease pathophysiology of obesity or AD. For 
instance, it is possible that a portion of any generated Aβ in adipose tissue could 
accumulate as amyloid deposits in either obese or AD individuals. It is well 
established that adipose tissue can accumulate amyloid proteins, for example, in 
individuals with rheumatoid arthritis which is often assessed via needle biopsy 
(Barile et al., 1993, Gomez-Casanovas et al., 2001).  
Our study of intestines was an effort to address another tissue type in 
which fatty acid uptake and immune cell activation were a critical part of normal 
or pathological change during many conditions. As expected, lack of APP again 
resulted in numerous changes in the behavior of macrophages in the small 
intestine resulting in specific cellular dysfunction in the form of altered cytokine 
profiles, motility, and absorption.  
Consistent with the idea that APP broadly regulates macrophage lineage 
cell phenotypes, our findings demonstrated that APP expression has profound 
regulatory effects on protein expression in a range of small intestine cells 
including neurons, CD68 positive macrophages, and enterocyte epithelial cells. 
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This represents, to the best of our knowledge, the first demonstration of a 
function for this protein in this manner.. Based upon the quantified differences in 
multiple cytokine expression levels as well as changes in intestinal motility and 
absorption it appears that APP has a role in gastrointestinal function as well.  
It is important to point out, just like in the adipose tissue, that it is not clear 
whether lack of APP on one or multiple cell types is responsible for the changes 
in cytokine profile, enterocyte protein expression or motility and absorption 
observed. Also, in spite of the robust changes in macrophage behavior and 
cytokine levels in APP-/- versus wild type mice, little detectable APP 
immunoreactivity was observed in macrophage-like cells in ileums of wild type 
mice. Based upon prior evidence of clear APP expression in monocytic lineage 
cells (Bauer et al., 1991, Bullido et al., 1996, Sondag and Combs, 2004b, 
Vehmas et al., 2004, Sondag and Combs, 2006a, 2010b, Spitzer et al., 2010) it is 
likely that the level of expression of APP in macrophages was simply not high 
enough to be detectable by the immunostaining procedure employed. Indeed, 
prior work from others has demonstrated in microglia that APP expression is 
upregulated when the cells are provided the appropriate stimulatory environment 
(Haass et al., 1991, Banati et al., 1994a, Monning et al., 1994, Banati et al., 
1995a, Banati et al., 1995b, Gehrmann et al., 1995a, Gehrmann et al., 1995b, 
Monning et al., 1995, Bullido et al., 1996, Vehmas et al., 2004, Itoh et al., 2009). 
In this fashion, it is likely that APP expression still directly regulates macrophage 
phenotype in the intestine in spite of the limitations in detection using the visible 
light chromagen method. One intriguing hypothesis is simply that macrophage 
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numbers are limited due to impaired ability of APP-/- cells to migrate into the 
submucosa and lamina propria. For instance, our prior work demonstrated that 
APP expression is required on both monocytes and endothelial cells for cell-cell 
interaction to occur necessary for monocytic adhesion required for activities such 
as diapedesis through the vasculature (Austin et al., 2009, Austin and Combs, 
2010). It is possible that APP-/- macrophages are limited in the intestine due to 
decreased influx through the vasculature. The impaired migratory ability of APP-/- 
macrophages supports this notion. 
On the other hand, it is also quite possible that APP and its proteolytic 
metabolites expressed on other cells, such as neurons or enterocytes are 
normally responsible for some level of CD68 positive macrophage numbers in 
the intestine. The robust detection of APP immunoreactivity that localized to 
enterocytes and neurons is entirely consistent with the fact that neurons 
particularly in the brain express large amounts of APP compared to other tissue 
types (Schmechel et al., 1988, Yamada et al., 1989, LeBlanc et al., 1991) and 
prior expression of at least the Aβ peptide, has been detected in rodent 
enterocytes (Galloway et al., 2007, Galloway et al., 2008, Galloway et al., 2009, 
Pallebage-Gamarallage et al., 2009). This suggests that lack of APP metabolites 
from neurons or enterocytes may lead to diminished stimulation of intestinal 
macrophages. Indeed, we as well as others have demonstrated in a plethora of 
studies that different multimeric forms of Aβ peptide or other APP fragments can 
directly stimulate immune cells such as monocytes, macrophages, and microglia 
to alter their phenotype (Klegeris et al., 1994, Yan et al., 1998, Combs et al., 
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1999, Yates et al., 2000, Smits et al., 2001, Yazawa et al., 2001, Ikezu et al., 
2003, Uryu et al., 2003, Xiong et al., 2004, Floden and Combs, 2006, Sondag et 
al., 2009, Maezawa et al., 2010). In this scenario, limited CD68 immunoreactivity 
in the APP-/- intestine could be a consequence of not only loss of macrophage 
APP function but also loss of APP metabolite-stimulated signaling of 
macrophages by neurons or enterocytes.  
Indeed, a lack of APP-dependent activation of immune cells or a lack of 
Aβ-dependent stimulation of immune cells in the ileum could possibly explain not 
only the decrease in CD68 protein levels but also other immune cells as well as 
the dramatic decrease in multiple cytokines in APP-/- intestines. This scenario 
suggests that perhaps APP or its metabolites offer some sort of basal or 
inducible stimulatory signal to help regulate gut function. However, as the 
premise of the current study was to first document a novel change in intestinal 
immune phenotype in APP-/- animals, further mechanistic dissection of the 
precise reason for changes in immune cell numbers or activation states remains 
a future goal. In fact, assessing changes in intestinal immune cell behavior as a 
consequence of APP expression and metabolism might be best addressed in the 
context of including animals that over-express human mutant APP characteristic 
of AD as we have done with the APP/PS1 data in this study. Provided that 
expression of the transgene occurs in the relevant cell types in the intestine, 
models such as these might offer insight into consequences of over-expression 
of APP or elevated Aβ levels on gut function and immune phenotype. More 
importantly, this might offer insight into consequences of mutant APP expression 
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in the gut as it relates to AD. It has already been demonstrated that Aβ 
immunoreactive plaques accumulate in the intestines of AD patients (Joachim et 
al., 1989) although evidence of enteric neuron loss is not established (Shankle et 
al., 1993, Van Ginneken et al., 2010). A role for APP or its proteolytic products in 
intestine function would provide not only insight into the immunoregulatory role of 
APP and its metabolites but also begin characterization of disease-relevant 
changes in a tissue other than the brain. 
Although the most straightforward clinical application of our data set is to 
extrapolate to conditions of AD as we have done in which mutant APP has a 
known role in the biology of disease, it is interesting to speculate that APP may 
ultimately have a role in modulating immune cell behavior in conditions other 
than AD. For instance, the changes in CD68 immunoreactivity observed in APP-/- 
mice combined with the cytokine profile changes suggests that systemic immune 
changes exist in these animals. We have only examined peritoneal macrophages 
and intestinal macrophages from the ileum in this study since our prior work has 
demonstrated a role for APP in monocytic lineage cell behavior (Sondag and 
Combs, 2004b, 2006a, 2010b). However, unlike the brain, the gut is home to a 
diverse population of dynamically changing and regulated immune cells that will 
likely be affected by any alteration of macrophage behavior. Indeed the 
decreased protein levels of CD40 and CD11c in the ileum suggest that levels or 
activation state of other immune cells such as B cells and dendritic cells are also 
altered in the in APP-/- mice.  
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Furthermore, for simplicity and proof-of-concept we have limited this 
assessment to the ileum of the small intestine based upon the fact that it contains 
immune cell infiltrates and a robust enteric nervous system. However, future 
efforts to generate a comprehensive profile of all immune cell changes not only in 
the ileum but throughout the digestive tract particularly the large intestine would 
offer cell and region specific information that could be correlated with plasma and 
other organ changes in cytokine and immune cell differences in APP-/- versus wild 
type mice.  
The change in Cox-2 protein levels in APP-/- mice certainly supports the 
idea that APP expression regulates gut function. A host of studies have 
documented a role for Cox-2 and its prostaglandin products in negatively 
regulating intestinal motility (Cong et al., 2007, Takechi et al., 2009, Fairbrother 
et al., 2011, Nylander, 2011, Shi et al., 2011). In addition, Cox-2 activity positively 
regulates intestine macrophage infiltration in a rodent model of sepsis (Osterberg 
et al., 2006) perhaps offering an additional mechanism explaining why APP-/- 
mouse CD68 positive macrophage immunoreactivity was attenuated compared 
to wild type mice. Therefore the decrease in Cox-2 protein levels observed in the 
APP-/- mice is entirely consistent with the increased motility and decreased water 
absorption observed in the collected stool samples. A change in absorptive 
capacity was further demonstrated by the significantly decreased levels of 
absorbed LPS in the APP-/- mice. The uptake of bacterial flora-derived LPS into 
plasma of rodents and humans as a consequence of lipid absorption is a well-
characterized phenomenon (Amar et al., 2008, Ghoshal et al., 2009). Although 
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this is not necessarily the only source for plasma LPS uptake, it correlates well 
with prior work and suggests that APP-/- intestines may also have impaired lipid 
absorption. In addition, although we did not detect significant differences in 
occludin protein levels between genotypes it is quite feasible that the integrity of 
the gut epithelial barrier is impaired in the APP-/- mice. Further work to provide 
additional measures of gut motility, barrier integrity, and absorption will better 
resolve the differences in gut function dependent upon expression of APP. 
Another interesting difference between APP-/- and wild type ileums was 
the decreased staining for MAP2 and the decrease in βIII-tubulin protein levels in 
the APP-/- mice. Based upon the role of the enteric nervous system in regulating 
absorption, secretion, and motility in the intestine it is feasible that the decrease 
in βIII-tubulin levels reflects a dysfunction of the enteric nervous control of the 
intestine. Future work examining more refined assessment of intestinal function 
will offer insight into this question. This may have nothing to do with enterocyte or 
immune cell function but instead be the consequence of loss of neuronal APP 
expression. Certainly, prior work examining the brains of APP-/- mice has 
demonstrated a similar decrease in MAP2 immunoreactivity (Seabrook et al., 
1999).  
It is important to point out that we compared intestinal and peritoneal 
macrophages in isolation when examining cytokine secretory phenotypes. 
Although this analysis clearly demonstrated differences not only between 
peritoneal and intestinal macrophages, it also verified that intestinal 
macrophages from APP-/- mice are unique from their wild-type counterparts. 
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Perhaps the more physiologically relevant comparison was derived from the 
cytokine array comparison of wild type and APP-/- ileums. This offered a broad 
screen of multiple cytokine changes that are a reflection of the more 
physiologically relevant multi-cell environment in vivo. Taking into account that 
the decreased levels of multiple cytokines in APP-/- ileums are still only a 
snapshot into the dynamic immune changes among multiple cell types that 
regulate the gut, the array nevertheless does offer an interesting speculative 
opportunity for hypothesizing how APP may have a role in diverse intestinal 
conditions.  For instance, it has been previously shown that CD30L plays a 
critical role in controlling inflammatory bowel syndrome in mice by increasing 
production of T-cells (Sun et al., 2008). Eotaxin mediates colonic eosinophilic 
inflammation (Waddell et al., 2011) and Fas Ligand has been shown to sequester 
double negative T cells in the gut epithelium (Hamad, 2010). Fractalkine can 
regulate increased IL-6 and TNFα release in the intestine (Niess and Adler, 
2010) and IL-12 production is increased by T-cells in irritable bowel disease (Uza 
et al., 2011).  
Therefore, since APP-/- mice have decreased levels of these multiple 
cytokines they may have decreased risk for inflammatory gut disease such as 
irritable bowel disease which could be investigated further. The decrease in 
GCSF could explain why APP-/- mice also have decreased dendritic cell marker 
protein, CD11c, as GCSF is the key factor in differentiating monocytes into 
dendritic cells (Metcalf, 1985).  IL-10, an anti-inflammatory cytokine, may be 
decreased due to the decrease in T-cell and macrophage expression as IL-10 
166 
 
has been shown to be a potent suppressor of macrophages and T-cells functions 
in vitro (Kuhn et al., 1993).  MIP-1γ may also be decreased due to the decrease 
in macrophage and dendritic cell numbers or activation as it is constitutively 
expressed in these cells (Mohamadzadeh et al., 1996, Haddad and Belosevic, 
2009). IL-9 has been shown to promote IL-13 up-regulation of innate immune 
receptors (Steenwinckel et al., 2009). Therefore the decrease in both IL-9 and IL-
13 observed is probably protective in these APP-/- mice as IL-13 has been shown 
to exert detrimental effects on epithelial barrier function by increasing epithelial 
cell apoptosis, derangement of tight junction integrity and acts as a key effector 
cytokine in ulcerative colitis (Heller et al., 2005).  MIG has also been shown to be 
concomitantly expressed in ulcerative colitis (Egesten et al., 2007).  TNFα has 
been implicated in the pathogenesis of Crohn’s disease, and by selectively 
blocking TNFR1 the severity of TNBS-induced colitis in rats is ameliorated (Yin et 
al., 2011). Again, the collective decrease in the multiple cytokines suggests that 
absence of APP attenuates gut inflammatory response perhaps influencing the 
susceptibility of these mice to gut inflammatory disease.   
We have taken some steps to determine consequences of AD mutant 
APP expression on intestinal function. As this is well described in brain already 
we intended, as already mentioned, to determine whether similar changes 
occurred in the intestines. With the understood caveat that APP/PS1 mice are 
not cell specific expression in any particular intestinal cell, the model provided an 
initial means of assessing whether the mutant represented a gain, loss, or no 
effect mutation in the intestine by comparison to the APP-/- mice. Based upon the 
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dramatic differences in APP-/- vs APP/PS1 intestines observed, we can 
tentatively conclude that the mutant expression behaves as a gain of function in 
the digestive tract. We demonstrated that overexpression of APP and possible 
metabolic cleavage in APP/PS1 mice increases immune cell deposition and 
regulates the protein expression of intestinal cells. Based upon the quantified 
increase in multiple cytokine expression levels as well as IgA secretion it again 
demonstrates that APP has a role in diverse tissue types including the intestine. 
In addition the expressed cytokine profile from the stimulated Caco-2 cells 
suggests that Aβ and LPS alter inflammation in the gut. Our results suggest that 
mutations in the gene coding for APP or altered processing of APP has effects in 
other tissues, such as the intestine, in addition or uniquely from any observed in 
the brain or adipose tissue. 
However, contrary to the results seen in our APP-/- mice, our APP/PS1 
mice have increased expression of APP as well as BACE in the intestine which is 
similar to the increase Aβ expression seen in the temporal cortex of our twelve 
month old APP/PS1 mice in previous studies of ours as well as others (Aso et al., 
2011, Dhawan and Combs, 2012).  This is also consistent with that seen in the 
brain of several sporadic AD studies (Holsinger et al., 2002, Yang et al., 2003, 
Fukumoto et al., 2004, Cai et al., 2010, Miners et al., 2011), suggesting that 
BACE expression levels correlate to increased β-amyloid production in the brain 
(Li et al., 2004). The deposition of Aβ in the intestines of these APP/PS1 mice is 
also consistent with the Aβ immunoreactive plaques reported to accumulate in 
the intestines of AD patients (Joachim et al., 1989). Once again, this suggests 
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that APP and its metabolites have disease relevance in tissues other than the 
brain.  Therefore, this increased Aβ in the intestine may contribute to the 
increased Aβ in the brain via β-amyloid’s ability to regulate apolipoprotein in the 
plasma. Aβ has been shown to colocalizes with chylomicron-apoB in enterocytes 
(Galloway et al., 2009) as well as in cerebral amyloid plaques (Takechi et al., 
2009) which has been correlated to increased plasma Aβ levels (Takechi et al., 
2009).  
 The prominent inflammatory changes in AD brain (Akiyama, 1994, 
Eikelenboom et al., 1994, Aisen, 1997, Akiyama et al., 2000, Rogers, 2008) are 
also evident in our APP/PS1 ileums evidenced by the increase in the 
inflammatory marker Cox-2, macrophage marker CD68, and the T cell marker 
CD3. This increase in CD68 immunoreactivity and levels are consistent with the 
increased reactive microglia numbers that are associated with Aβ plaque 
pathology in the AD brain (McGeer et al., 1987, Akiyama and McGeer, 1990, 
Cras et al., 1990, Styren et al., 1990, Wood and Zinsmeister, 1991, Frautschy et 
al., 1998, Stalder et al., 1999, Wegiel et al., 2001, Sasaki et al., 2002, Dhawan 
and Combs, 2012). Increased CD68 positive macrophage could be due to the 
increase in cox-2. As previously stated, Cox-2 activity positively regulates 
intestinal macrophage infiltration in a rodent model of sepsis (Osterberg et al., 
2006). The increase in T cells seen in the intestine is also consistent with reports 
from a number of AD patient studies that have shown more T-cells activated in 
AD patients than age-matched controls both in the periphery and brain (Togo et 
al., 2002, Town et al., 2005, Li et al., 2009).  These data suggest that peripheral 
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accumulation of immune cells may possibly contribute to the increased immune 
cells population seen in the AD brain.  
 Along with Cox-2 there was a significant increase in CD36 levels in spite 
of no difference in occludin levels which were used as additional markers for 
assessing intestinal integrity.  Active transport (Schulzke et al., 2005) and 
intestinal barrier integrity (Al-Sadi et al., 2011) have been shown to be regulated 
by occludin in mice both in knockout and in vivo siRNA studies, respectively. 
However, CD36 is also a critical fatty acid uptake regulatory protein suggesting 
that these APP/PS1 mice have increased dietary fatty acid and cholesterol 
uptake necessary for chylomicron formation (Nassir et al., 2007). The possibility 
of increased chylomicron formation fits very nicely with the increase in Aβ 
immunoreactivity we observed. As stated before, Aβ colocalizes with 
chylomicron-apoB in enterocytes (Galloway et al., 2009) and may lead to an 
increase in plasma Aβ levels. 
 Another interesting difference between APP/PS1 and wild type ileums was 
the equally robust staining for MAP2 and synaptophysin, consistent with the 
significant increase in protein levels of both the pre-synaptic marker, 
synaptophysin and the post-synaptic marker, PSD95, in the APP/PS1 mice.  This 
is consistent with previous studies that have implicated a role for APP expression 
in regulating both pre-synaptic and post-synaptic integrity in the central and 
peripheral nervous system (Seabrook et al., 1999, Yang et al., 2005, Priller et al., 
2006, Hoe et al., 2009, Wang et al., 2009, Lee et al., 2010, Weyer et al., 2011). 
Although differences in synaptic markers could indicate changes in neuron 
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numbers, hypertrophy, or sprouting responses in the APP/PS1 mice, we have not 
yet determined whether this occurs. Indeed, prior work in humans and AD mouse 
models has also not established whether neuron loss occurs in the enteric 
nervous system (Shankle et al., 1993, Van Ginneken et al., 2010). Since the 
enteric nervous system regulates absorption, secretion and motility in the 
intestine and we did not observe dramatic changes in motility or water 
absorption, it appears that the enteric system of the mice is not compromised at 
this age by overexpression of mutant APP or its metabolites.  
 As with lack of APP expression in the intestine (Puig et al., 2012), it is still 
not clear whether overexpression of APP in one or multiple cell types is 
responsible for the changes in immune cell number, cytokine profile, enterocytes 
protein expression, or mucosal secretion observed. Robust immunoreactivity of 
APP was observed in both enterocytes and neurons and both are clearly capable 
of metabolizing APP to Aβ.This suggested that mutant APP in either cell type 
might be responsible for all the changes observed. Because little detectable APP 
immunoreactivity was observed in macrophage in ileums of APP/PS1 and wild 
type mice, intestinal macrophage may be increased in the APP/PS1 mice due to 
increased migratory ability of peripheral macrophage.  Our prior work 
demonstrated that monocytic adhesion and diapedesis through the vasculature 
requires APP expression on both monocytes and endothelial cells (Austin et al., 
2009, Austin and Combs, 2010). Therefore, although we have not examined it, 
elevated APP expression on endothelial cells may facilitate increased recruitment 
of macrophage into the intestine.  On the other hand, the numbers of overall 
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macrophage in the intestine may not be increased in the APP/PS1 mice but 
instead simply have increased reactivity. We, as well as numerous other groups, 
have demonstrated that different multimeric forms of Aβ peptide or other APP 
fragments can directly stimulate immune cells and alter their phenotype (Klegeris 
et al., 1994, Yan et al., 1998, Combs et al., 1999, Yates et al., 2000, Smits et al., 
2001, Yazawa et al., 2001, Ikezu et al., 2003, Uryu et al., 2003, Xiong et al., 
2004, Sondag et al., 2009, Maezawa et al., 2010). In addition, we have observed 
that Acan be taken up by, secreted by, and stimulates enterocyte Caco-2 cells. 
This APP metabolite-stimulated signaling of macrophages leading to elevated 
CD68 and even CD3 immunoreactivity could result from neuron or enterocyte 
secreted products and explain the increase in multiple cytokines in the APP/PS1 
intestine.  
Indeed, the diverse cytokine changes observed in the APP/PS1 intestine 
provides insight into the dynamic immune changes that occur in regulating the 
gut due to the presence of multiple cell types. For instance, in irritable bowel 
disease IL-12 production is increased by T-cells (Uza et al., 2011). LIX, also 
known as epithelial-derived neutrophil-activating peptide 78 (ENA-78), 
expression is increased in mice with dextran sodium sulfate induced colitis (Kwon 
et al., 2005) and also has been shown to play an important role in neutrophil 
recruitment from the lamina propria into the epithelial layer of the intestine 
(Keates et al., 1997). In general, monocyte chemoattractant protein-1 (MCP-1) 
plays an important role in recruitment of monocytes and macrophages to 
inflamed tissues (Yoshimura and Leonard, 1992). Macrophage-colony stimulating 
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factor (MCSF) influences monocyte/macrophage proliferation, differentiation, 
activation and is increased in inflammatory bowel disease (IBD) (Klebl et al., 
2001). Both the increase in MCP-1 and MCSF are consistent with the increased 
CD68 immunoreactivity in these APP/PS1 mice. Stromal cell-derived factor-1 
(SDF-1) also known as CXCL12 is also increased in IBD (Dotan et al., 2010), 
and tissue inhibitor of metalloproteinases 1 (TIMP-1) is increased in IBD (Naito 
and Yoshikawa, 2005), especially in ulcerative colitis (Wiercinska-Drapalo et al., 
2003, Wang and Yan, 2006). The collective increase in cytokines associated with 
IBD suggests that the increase in APP, and its metabolite Aβ, may increase the 
susceptibility of these mice to gut inflammatory disease and once again supports 
our hypothesis that APP has a key role in modulating immune cell behavior in 
conditions other than AD. 
We ultimately expect that a number of conditions involving immune cell 
behavior in the gut, such as irritable bowel syndrome and Crohn’s disease, may 
well be altered in the absence of APP expression. Moreover, a role for APP in 
regulating immune responses may extend well beyond the gut to include 
conditions of immune dysfunction as varied as asthma and respiratory allergies 
since immune cells within the gastrointestinal system are not confined to this 
organ system but are free to migrate throughout the body. Future work to identify 
the extent of various immune cell phenotype changes dependent upon specific 
functions of APP or its metabolites will validate the role of this protein not only 
during normal physiology but a variety of diseases. 
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The structure and processing of APP is well described even though the 
function of the full length protein and its many metabolites remains unclear. This 
is compounded by the fact that the biology of this protein may be different 
depending upon the cell type or tissue involved.  Indeed the bulk of our findings 
in this study as well as our prior work demonstrating that microglia and not 
neurons or astrocytes initiate a tyrosine kinase-dependent signaling response 
downstream of APP activation support this idea. Defining the function of APP and 
its proteolytic fragments in a cell-by-cell fashion will likely provide insight into not 
only Alzheimer’s disease but myriad disease conditions such as psoriasis, 
obesity, gut inflammatory disease, inclusion-body myositis and other diseases of 
peripheral tissues. In fact, determining the behavior of APP and its products in 
peripheral cells may, by comparison, better define their normal and disease 
actions in neurons or within the brain since even this behavior remains unclear. 
For instance, appreciating the peripheral distribution and processing of APP may 
define mechanisms for increases in circulating Aβ levels which could cross the 
blood-brain-barrier and contribute to brain parenchymal Aβ load during AD 
(Mackic et al., 2002). More importantly, there exists the tantalizing possibility that 
targeting generation or function of APP and its breakdown products might be 
therapeutically applicable to conditions beyond AD. Perhaps even more intriguing 
is the fact that mutations in the gene coding for APP are responsible for the 
autosomal dominant forms of Alzheimer's disease (Goate et al., 1991). 
Therefore, it is likely not by coincidence then, that obesity is a risk factor for this 
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Alzheimer’s disease (Razay and Vreugdenhil, 2005, Razay et al., 2006, 2007, 
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